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Introduction {#opo12675-sec-0004}
============

Age‐related macular degeneration (AMD) is a degenerative disease of the macula, often leading to progressive vision loss. AMD is the most prevalent retinal disease in the Western world with approximately 1--3% of the total population suffering from an advanced stage of the disease.[1](#opo12675-bib-0001){ref-type="ref"}, [2](#opo12675-bib-0002){ref-type="ref"}, [3](#opo12675-bib-0003){ref-type="ref"} The rate of disease progression can vary among individuals and studies have identified several risk factors for a faster disease progression. The potential benefit of identifying these risk factors is the ability to predict disease progression in individual patients but also to improve the design of clinical trials. With the development of new imaging techniques and the progress in genetic and molecular technologies, new risk factors for disease progression have been identified but not all have been assessed in comprehensive prediction models.

Aim of this review {#opo12675-sec-0005}
------------------

The aim of this review is to provide an overview of the current literature investigating phenotypic, demographic, environmental, genetic, and molecular risk factors for disease progression in age‐related macular degeneration. In addition, we describe the most promising risk factors that could improve current prediction models for personalised healthcare.

Methods of literature search {#opo12675-sec-0006}
----------------------------

A comprehensive review of literature was performed through a PubMed search in July 2019. We used the following keywords and their synonyms in various combinations: age‐related macular degeneration, prospective cohort study, follow‐up, progression, risk factors and prediction. When a specific risk factor was identified, the specific risk factor was also used as a keyword in a second PubMed search to identify additional publications with prospective data on the specific risk factor. Articles cited in the reference list of articles obtained through this search were also reviewed whenever relevant. After article selection, all specific risk factors were grouped based on their corresponding risk category and results were discussed accordingly. A complete overview of the studies and references is provided in Tables [S1--S6](#opo12675-sup-0001){ref-type="supplementary-material"}.

Definition of progression in age‐related macular degeneration {#opo12675-sec-0007}
-------------------------------------------------------------

Disease progression in AMD has been defined using various approaches. Although deteriorating vision seems a logical outcome measure for defining AMD progression in natural history studies or clinical trials, it is often unrealistic to use visual acuity as an endpoint since vision loss may take years to develop. For this reason, studies on AMD have used anatomical endpoints to measure disease progression over a relatively short time span.[4](#opo12675-bib-0004){ref-type="ref"} The most often used anatomical endpoint in AMD is the development of late AMD, which can be divided into two subtypes: geographic atrophy (GA) and choroidal neovascularisation (CNV).

### Progression to geographic atrophy {#opo12675-sec-0008}

GA, also referred to as dry AMD, is characterised by the loss of photoreceptors, retinal pigment epithelium (RPE) and choriocapillaris, causing a gradual loss of vision over time.[5](#opo12675-bib-0005){ref-type="ref"}, [6](#opo12675-bib-0006){ref-type="ref"} AMD progression can be defined as the conversion of an early stage of AMD to GA.[4](#opo12675-bib-0004){ref-type="ref"} Three major imaging strategies have been used to document conversion to GA: colour fundus photography (CFP), fundus autofluorescence (FAF) and optical coherence tomography (OCT). On CFP it can be challenging to identify early signs of GA development and to reliably establish the margins of GA, whereas FAF and OCT imaging are more suitable for this purpose. On FAF, GA is identified by the absence of a fluorescence signal, which is assumed to correlate with the absence of RPE, delineating the boundaries of the GA lesion.[7](#opo12675-bib-0007){ref-type="ref"} However, FAF imaging does not always reveal a GA lesion when OCT imaging detects GA.[8](#opo12675-bib-0008){ref-type="ref"} The Classification of Atrophy Meetings (CAM) program proposed the OCT as the standard reference or base imaging method to diagnose and stage GA.[9](#opo12675-bib-0009){ref-type="ref"} GA can develop into different stages, depending on the disappearance of the photoreceptor layer and RPE layer. According to the CAM classification, GA can be subdivided into: incomplete outer retina atrophy (iORA, demonstrating thinning of the outer retina with an intact RPE band and no hypertransmission of light into the choroid below Bruch\'s membrane (BM)), complete outer retina atrophy (cORA, showing severe thinning of the outer retina, in the setting of an intact RPE band with intermittent hypertransmission of light), incomplete RPE and outer retinal atrophy (iRORA, showing the degeneration of photoreceptors, an irregular or interrupted RPE band and discontinued hypertransmission of light) and finally complete RPE and outer retinal atrophy (cRORA, showing the degeneration of photoreceptors and a zone of complete disrupted RPE band of at least 250 µm in diameter with the hypertransmission of light).

### Geographic atrophy growth {#opo12675-sec-0009}

When GA has already developed, the growth rate of GA may be used as a quantifiable measure for disease progression.[4](#opo12675-bib-0004){ref-type="ref"} Clinical trials have been using the GA growth rate as an outcome measurement to investigate the effects of new developed drugs. These studies use mainly CFP or FAF imaging to measure the growth of the GA lesions. Yet, OCT is recommended as the standard reference to define the borders of the GA lesion.[9](#opo12675-bib-0009){ref-type="ref"}

### Progression to neovascular age‐related macular degeneration {#opo12675-sec-0010}

CNV, also referred to as wet AMD or neovascular AMD (nAMD) is characterised by the formation of new fragile vessels that originate from the choriocapillaris. These new vessels grow into the retina with subsequent leakage and/or hemorrhage, which can result in serous RPE detachment accompanied by a rapid loss of vision and eventually provoking a vision‐threatening scar in the macula.[10](#opo12675-bib-0010){ref-type="ref"} Imaging modalities that can identify the conversion of an early stage of AMD to nAMD are CFP, OCT, fluorescein angiography (FAG), indocyanine green angiography (ICGA) and OCT‐angiography (OCTA). Whereas CFP, OCT, and FAG can identify exudative nAMD by fluid leakage and haemorrhaging, in some cases a CNV can already be visualised before exudation occurs using ICGA and OCTA imaging.[11](#opo12675-bib-0011){ref-type="ref"}

### Progression at early disease stages {#opo12675-sec-0011}

Central GA and nAMD are strongly associated with the loss of vision, but both advanced stages can take years to develop. Therefore, conversion to GA or nAMD is not always the best outcome measure for disease progression in natural history studies or clinical trials. In addition, advanced stage AMD may be too late in the disease process to demonstrate the effectiveness of newly developed treatments, which may be more effective when administered earlier in the disease process.[4](#opo12675-bib-0004){ref-type="ref"} Therefore, several AMD severity scales have been developed in an effort to provide endpoints to monitor AMD progression at earlier disease stages.[12](#opo12675-bib-0012){ref-type="ref"}, [13](#opo12675-bib-0013){ref-type="ref"} The most commonly used anatomical endpoints in these severity scales are the appearance and progression of drusen, but also other phenotypic features that are associated with the development of advanced stage AMD, can be used to investigate disease progression at earlier disease stages. In this review, we included prospective studies that evaluated the incidence of early AMD (based on the appearance of drusen and/or pigment abnormalities), as well as the progression to late AMD, including GA and nAMD, and GA growth.

Phenotypic risk factors {#opo12675-sec-0012}
=======================

Drusen {#opo12675-sec-0013}
------

Drusen are deposits of extracellular debris between the retinal pigment epithelium (RPE) and Bruch\'s membrane (BM). Drusen may be a manifestation of the normal ageing process or can represent an early sign of AMD, depending on the number, size, shape, distribution, and morphology of the drusen.[14](#opo12675-bib-0014){ref-type="ref"} Studies have shown that drusen are dynamic structures that demonstrate repeated cycles of increased and decreased volume, but, overall, drusen are more likely to grow.[15](#opo12675-bib-0015){ref-type="ref"}, [16](#opo12675-bib-0016){ref-type="ref"} When individual drusen decrease in size, they may result in no residual anatomic defects or they may evolve into GA or nAMD.[17](#opo12675-bib-0017){ref-type="ref"}, [18](#opo12675-bib-0018){ref-type="ref"}, [19](#opo12675-bib-0019){ref-type="ref"}, [20](#opo12675-bib-0020){ref-type="ref"} The total number of drusen or measured drusen area or volume, are risk factors for the progression to GA and nAMD.[16](#opo12675-bib-0016){ref-type="ref"}, [17](#opo12675-bib-0017){ref-type="ref"}, [21](#opo12675-bib-0021){ref-type="ref"}, [22](#opo12675-bib-0022){ref-type="ref"}, [23](#opo12675-bib-0023){ref-type="ref"}, [24](#opo12675-bib-0024){ref-type="ref"}, [25](#opo12675-bib-0025){ref-type="ref"}, [26](#opo12675-bib-0026){ref-type="ref"} Also, the location of the drusen is of predictive value for disease progression, since eyes with drusen near the fovea have a higher probability of developing late AMD compared to eyes with drusen outside the fovea.[21](#opo12675-bib-0021){ref-type="ref"}, [23](#opo12675-bib-0023){ref-type="ref"}, [27](#opo12675-bib-0027){ref-type="ref"} Although CFP is useful for assessing the appearance of drusen, multimodal imaging can be used to distinguish subtypes of drusen.[28](#opo12675-bib-0028){ref-type="ref"}

### Small drusen {#opo12675-sec-0014}

Small drusen are classified as discrete yellow‐white deposits (≤63 µm in diameter) with clear defined margins and are located between the RPE and BM (*Figure* [1](#opo12675-fig-0001){ref-type="fig"}).[14](#opo12675-bib-0014){ref-type="ref"} Individuals over 55 years of age with a few small drusen, called "drupelets", which are considered to be a normal ageing process of the eye, have a low probability (0.4%) of developing late AMD within five years.[29](#opo12675-bib-0029){ref-type="ref"} Nevertheless, AMD frequently begins with small drusen, which might accumulate in number over time.

![Hard druse on colour fundus photograph, as indicated with an arrow (left) and optical coherence tomography, as indicated with an arrow (right).](OPO-40-140-g001){#opo12675-fig-0001}

### Medium and large drusen {#opo12675-sec-0015}

Medium drusen (\>63 µm and ≤125 µm in diameter) and large drusen (\>125 µm in diameter) are large focal yellow‐white deposits with unclearly defined margins and are located between the BM and RPE, most often in the central macula (*Figure* [2](#opo12675-fig-0002){ref-type="fig"}).[14](#opo12675-bib-0014){ref-type="ref"} In the most grading protocols, patients with medium drusen without pigmentary abnormalities are considered to have early stage AMD. Patients with medium drusen and pigmentary abnormalities, or with at least large drusen have intermediate stage AMD.[29](#opo12675-bib-0029){ref-type="ref"} Especially large drusen are associated with progression towards late stage AMD, in particular GA.[18](#opo12675-bib-0018){ref-type="ref"}, [20](#opo12675-bib-0020){ref-type="ref"}, [23](#opo12675-bib-0023){ref-type="ref"}, [30](#opo12675-bib-0030){ref-type="ref"}, [31](#opo12675-bib-0031){ref-type="ref"}, [32](#opo12675-bib-0032){ref-type="ref"} Depending on the absence or presence of pigment abnormalities, patients with medium drusen have a probability between 2% and 20% of developing late AMD within five years, while patients with large drusen have a probability between 13% and 47% of developing late AMD within five years.[29](#opo12675-bib-0029){ref-type="ref"} Large drusen that increase rapidly in size over time are more at risk for RPE cell migration upon the druse with eventually a drusen collapse and the formation of GA.[33](#opo12675-bib-0033){ref-type="ref"}, [34](#opo12675-bib-0034){ref-type="ref"}

![Large drusen on colour fundus photograph, as indicated with an arrow (left) and optical coherence tomography, as indicated with arrows (right).](OPO-40-140-g002){#opo12675-fig-0002}

### Calcified drusen {#opo12675-sec-0016}

When drusen exist for a longer duration, they can undergo calcification which gives the druse a glistening appearance on CFP. On OCT, calcified drusen can be identified as a druse with heterogeneous hyperreflective structures. (*Figure* [3](#opo12675-fig-0003){ref-type="fig"}).[14](#opo12675-bib-0014){ref-type="ref"} Calcification of drusen is usually a sign of drusen regression, with eventually the development of RPE atrophy above the druse leading to GA.[18](#opo12675-bib-0018){ref-type="ref"}, [35](#opo12675-bib-0035){ref-type="ref"}, [36](#opo12675-bib-0036){ref-type="ref"}. Patients with calcified drusen have a probability of 26% of developing GA within five years.[35](#opo12675-bib-0035){ref-type="ref"}

![Calcified druse on colour fundus photograph, as indicated with an arrow (left) and optical coherence tomography, as indicated with an arrow (right).](OPO-40-140-g003){#opo12675-fig-0003}

### Reticular pseudodrusen {#opo12675-sec-0017}

Reticular pseudodrusen (RPD) are dot‐like subretinal deposits between the RPE and photoreceptor layer which most frequently first appear in the upper part of the retina and then extend towards the macula over time, forming interlacing networks.[14](#opo12675-bib-0014){ref-type="ref"} Although visible on CFP, RPD are best visualised using near‐infrared (NIR) photography.[37](#opo12675-bib-0037){ref-type="ref"} Using CFP and NIR photography, RPD can still easily be misdiagnosed for small drusen. OCT is needed to confirm the RPD by their position between the RPE and photoreceptor layer (*Figure* [4](#opo12675-fig-0004){ref-type="fig"}).[28](#opo12675-bib-0028){ref-type="ref"} RPD are highly prevalent in fellow‐eyes of patients with unilateral nAMD. Although these patients with unilateral nAMD are at high risk of progression, observing the presence of RPD in fellow‐eyes renders an additional risk of progression.[30](#opo12675-bib-0030){ref-type="ref"}, [32](#opo12675-bib-0032){ref-type="ref"}, [38](#opo12675-bib-0038){ref-type="ref"}, [39](#opo12675-bib-0039){ref-type="ref"} RPD are of prognostic significance in the progression of AMD and are independently associated with progression towards GA (progression rate of 15.3% in two years) and nAMD (progression rate of 30.7% in two years) regardless of the disease stage based on other features.[23](#opo12675-bib-0023){ref-type="ref"}, [30](#opo12675-bib-0030){ref-type="ref"}, [32](#opo12675-bib-0032){ref-type="ref"}, [38](#opo12675-bib-0038){ref-type="ref"}, [39](#opo12675-bib-0039){ref-type="ref"}, [40](#opo12675-bib-0040){ref-type="ref"}, [41](#opo12675-bib-0041){ref-type="ref"} In addition, dot pseudodrusen are more often associated with the development of nAMD (relative risk \[RR\] 2.53), while confluent pseudodrusen are associated with the development of GA (RR 4.35).[41](#opo12675-bib-0041){ref-type="ref"} Eyes with RPD have also an increased probability of GA growth within three years follow‐up (74--77%) compared to eyes without RPD (42--53%).[42](#opo12675-bib-0042){ref-type="ref"}, [43](#opo12675-bib-0043){ref-type="ref"}

![Reticular pseudodrusen on colour fundus photograph (left), near‐infrared photography (middle) and optical coherence tomography, as indicated with arrows (right).](OPO-40-140-g004){#opo12675-fig-0004}

### Cuticular drusen {#opo12675-sec-0018}

Cuticular drusen are multiple small drusen that may cluster between the BM and RPE layer, often first visible in the peripheral retina and later in the macula.[14](#opo12675-bib-0014){ref-type="ref"} Cuticular drusen have a characteristic hyperfluorescent stars‐in‐the‐sky appearance, which is best identified using FAG. Individually they may be mistaken for small drusen or dot RPD, but because of their saw‐tooth appearance and spheroid or triangular shape on OCT, they can still be identified as cuticular drusen (*Figure* [5](#opo12675-fig-0005){ref-type="fig"}).[28](#opo12675-bib-0028){ref-type="ref"} Genetic studies show, cuticular drusen are associated with variants in the *CFH* gene.[44](#opo12675-bib-0044){ref-type="ref"} They are predictive for the development of nAMD (progression probability of 8.7%‐12.5% in five years) and GA (progression probability of 25.0%‐28.4% in five years).[45](#opo12675-bib-0045){ref-type="ref"}, [46](#opo12675-bib-0046){ref-type="ref"}

![Cuticular drusen on colour fundus photograph (left), fluorescein angiography (middle) and optical coherence tomography, as indicated with arrows (right).](OPO-40-140-g005){#opo12675-fig-0005}

Changes of the retinal pigment epithelium {#opo12675-sec-0019}
-----------------------------------------

### Pigmentary changes {#opo12675-sec-0020}

Pigmentary changes in the macula are a feature of early AMD. Pigmentary changes appear on CFP either as hypopigmentation, which is seen as depigmented areas of the RPE not meeting criteria for GA, or as hyperpigmentation, which are deposits of pigment from the RPE within the retina (*Figure* [6](#opo12675-fig-0006){ref-type="fig"}). The involvement of pigmentary changes in addition to drusen increases the risk of developing late AMD drastically.[20](#opo12675-bib-0020){ref-type="ref"}, [21](#opo12675-bib-0021){ref-type="ref"}, [23](#opo12675-bib-0023){ref-type="ref"}, [30](#opo12675-bib-0030){ref-type="ref"}, [31](#opo12675-bib-0031){ref-type="ref"}, [47](#opo12675-bib-0047){ref-type="ref"} Patients with large drusen and pigmentary changes have a probability of 47% of developing late AMD within five years.[29](#opo12675-bib-0029){ref-type="ref"}

![Hyperpigmentation on top of a large druse on colour fundus photograph, as indicated with an arrow (left), hyperreflective foci (indicated with arrow) upon a drusenoid pigment epithelial detachment (indicated between dotted lines) on optical coherence tomography (right).](OPO-40-140-g006){#opo12675-fig-0006}

### Hyperreflective foci {#opo12675-sec-0021}

Hyperreflective foci (HRF) on OCT are lesions of equal or higher reflectivity than the RPE band, located in the neuroretina, often above drusen, and are associated with the hyperpigmentation on CFP (*Figure* [6](#opo12675-fig-0006){ref-type="fig"}).[48](#opo12675-bib-0048){ref-type="ref"} Studies suggest that HRF may represent the migration of RPE cells caused by cytokines and inflammatory mediators in response to oxidative stress and complement activation.[49](#opo12675-bib-0049){ref-type="ref"} HRF are associated with progression to nAMD and GA,[17](#opo12675-bib-0017){ref-type="ref"}, [19](#opo12675-bib-0019){ref-type="ref"}, [50](#opo12675-bib-0050){ref-type="ref"}, [51](#opo12675-bib-0051){ref-type="ref"} and the progression rates seems to be the same for both late AMD stages: 47% of eyes with HRF develop nAMD after 24 months,[52](#opo12675-bib-0052){ref-type="ref"} and 50% of eyes with HRF develop GA within 28 months.[53](#opo12675-bib-0053){ref-type="ref"}

### Pigment epithelial detachment {#opo12675-sec-0022}

Pigment epithelial detachment (PED) is characterised by the separation of the RPE from the BM. PEDs can be classified into fibrovascular, serous and drusenoid types. Fibrovascular PEDs and serous PEDs are both associated with nAMD and are caused by the accumulation of fluid between the BM and RPE. On OCT, fibrovascular PEDs are RPE detachments which have a flattened or notched border and are frequently associated with a hidden CNV (see section on Quiescent choroidal neovascularisation NV/Subclinical choroidal neovascularisation). Serous PEDs appear as a large dome‐shaped detachment of the RPE and are thought to develop by an increased hydrostatic pressure from an underlying CNV.[54](#opo12675-bib-0054){ref-type="ref"} Drusenoid PEDs develop from the coalescence of drusen and are associated with the progression to GA (probability of 19% within five years),[18](#opo12675-bib-0018){ref-type="ref"}, [47](#opo12675-bib-0047){ref-type="ref"}, [55](#opo12675-bib-0055){ref-type="ref"}, [56](#opo12675-bib-0056){ref-type="ref"} progression to nAMD (probability of 23% within five years)[47](#opo12675-bib-0047){ref-type="ref"}, [50](#opo12675-bib-0050){ref-type="ref"}, [53](#opo12675-bib-0053){ref-type="ref"}, [55](#opo12675-bib-0055){ref-type="ref"}, [56](#opo12675-bib-0056){ref-type="ref"} and the development of calcified drusen and pigmentary changes (*Figure* [6](#opo12675-fig-0006){ref-type="fig"}).[47](#opo12675-bib-0047){ref-type="ref"}

Geographic atrophy features {#opo12675-sec-0023}
---------------------------

### Lesion size {#opo12675-sec-0024}

Several studies have attempted to identify features of the GA lesions that are predictive for faster GA enlargement. Natural history studies show that the GA enlargement is dependent on the baseline GA area, showing an exponential increase in GA area over time. [57](#opo12675-bib-0057){ref-type="ref"}, [58](#opo12675-bib-0058){ref-type="ref"}, [59](#opo12675-bib-0059){ref-type="ref"}, [60](#opo12675-bib-0060){ref-type="ref"}, [61](#opo12675-bib-0061){ref-type="ref"}, [62](#opo12675-bib-0062){ref-type="ref"} Of note, some studies suggest that this acceleration is dependent on the GA lesion at a specific time point, showing an acceleration of the GA growth in earlier stages of GA and deacceleration of GA growth at later stages of GA when there are no remaining RPE cells in the macula.[4](#opo12675-bib-0004){ref-type="ref"}, [63](#opo12675-bib-0063){ref-type="ref"} However, when the GA enlargement is adjusted for the baseline lesion size by using a square root transformation, the lesion itself seems to have less influence on the GA growth. These studies report a mean GA enlargement between 0.23--0.28 mm year^−1^, independent of the lesion size.[61](#opo12675-bib-0061){ref-type="ref"}, [62](#opo12675-bib-0062){ref-type="ref"}, [63](#opo12675-bib-0063){ref-type="ref"}, [64](#opo12675-bib-0064){ref-type="ref"}

### Lesion number and location {#opo12675-sec-0025}

Multiple studies have reported increased rates of GA growth in eyes with multifocal lesions (0.32--0.42 mm year^−1^ or 0.9--1.97 mm^2^ year^−1^) as compared to eyes with unifocal lesions (0.19--0.26 mm year^−1^ or 0.3--1.05 mm^2^ year^−1^).[42](#opo12675-bib-0042){ref-type="ref"}, [43](#opo12675-bib-0043){ref-type="ref"}, [59](#opo12675-bib-0059){ref-type="ref"}, [61](#opo12675-bib-0061){ref-type="ref"}, [62](#opo12675-bib-0062){ref-type="ref"} Multifocal lesions may have increased GA growth since they have a larger border of the active disease process. The location of the lesion is also found to be associated with the progression of the GA. Extrafoveal lesions seem to have faster growth rates (0.31--0.33 mm year^−1^ or 2.05 mm^2^ year^−1^) when compared to foveal lesions (0.22--0.27 mm year^−1^ or 1.28 mm^2^ year^−1^).[57](#opo12675-bib-0057){ref-type="ref"}, [59](#opo12675-bib-0059){ref-type="ref"}, [62](#opo12675-bib-0062){ref-type="ref"}, [63](#opo12675-bib-0063){ref-type="ref"}

### Lesion shape {#opo12675-sec-0026}

The shape of the GA lesion is also an indicator of disease progression. One study showed that the Geographic Atrophy Circularity Index (GACI), a measurement of the circularity of the GA lesion based on the GA area and its perimeter, is associated with the progression rate of GA. GA lesions with a circular shape (GACI \> 0.75) have a slower growth rate (0.21 mm year^−1^) when compared to GA lesions with an irregular shape (GACI \< 0.25, 0.40 mm year^−1^).[62](#opo12675-bib-0062){ref-type="ref"}

### Perilesional fundus autofluorescence pattern {#opo12675-sec-0027}

The perilesional FAF pattern surrounding the GA lesions has been shown to correlate with the growth rates of GA. These FAF patterns can be subdivided into multiple categories, based on the position of the hyperfluorescence. (*Figure* [7](#opo12675-fig-0007){ref-type="fig"}). Progression rates of GA are lower in eyes with no FAF patterns (0.20--0.38 mm^2^ year^−1^) and focal FAF patterns (0.53--0.81 mm^2^ year^−1^), while progression rates of GA are higher in eyes with banded (1.69--1.81 mm^2^ year^−1^) and diffuse FAF patterns (1.74--1.77 mm^2^ year^−1^). These results have been replicated in multiple studies.[59](#opo12675-bib-0059){ref-type="ref"}, [65](#opo12675-bib-0065){ref-type="ref"}, [66](#opo12675-bib-0066){ref-type="ref"}, [67](#opo12675-bib-0067){ref-type="ref"} However, one prospective study reported that the effect of the perilesional FAF pattern on GA growth is mainly caused by the baseline lesion size, suggesting that the perilesional FAF pattern is a consequence of GA growth and not the cause.[57](#opo12675-bib-0057){ref-type="ref"}

![Overview of perilesional fundus autofluorescence patterns, from left to right: no pattern (a), focal pattern (b), banded pattern (c) and diffuse pattern (d).](OPO-40-140-g007){#opo12675-fig-0007}

Vascular features {#opo12675-sec-0028}
-----------------

### Choroidal abnormalities {#opo12675-sec-0029}

Several studies found evidence for the importance of the choroid in the pathogenesis of AMD established that the choroid vascular structures deplete in eyes with early AMD, GA and nAMD.[68](#opo12675-bib-0068){ref-type="ref"}, [69](#opo12675-bib-0069){ref-type="ref"} One prospective study identified that irregular choroidal vessels are predictive for both the development of GA and nAMD.[50](#opo12675-bib-0050){ref-type="ref"} In addition, a smaller choroidal thickness was associated with the development of GA in one prospective study,[19](#opo12675-bib-0019){ref-type="ref"} but these findings could not be replicated.[32](#opo12675-bib-0032){ref-type="ref"}

### Choriocapillaris flow impairments {#opo12675-sec-0030}

OCT angiography (OCTA) can detect blood flow by analysing changes in tissue reflectivity between rapidly acquired images, visualising the blood flow of the retina and the choroidal vasculature. Although OCTA is still developing as an imaging modality, it has already demonstrated some potential features for predicting GA growth. Flow impairment in the choriocapillaris surrounding the atrophic lesions was associated with the increased GA growth rate over 1.3 years of follow‐up in one study.[70](#opo12675-bib-0070){ref-type="ref"} However, these findings have not yet been replicated.

### Quiescent choroidal neovascularisation/Subclinical choroidal neovascularisation {#opo12675-sec-0031}

Using ICGA or OCTA, it is also possible to visualise a CNV in nAMD before exudation occurs (*Figure* [8](#opo12675-fig-0008){ref-type="fig"}). When these treatment‐naïve CNVs present over at least 6 months without any signs of exudation, these CNVs are defined as quiescent CNVs or subclinical CNVs.[71](#opo12675-bib-0071){ref-type="ref"} Quiescent CNVs appear as a hyperfluorescent plaque on ICGA, and as a network of vessels between the BM and RPE on OCTA. On OCT, a double layer sign can be identified at the site of the quiescent CNV, showing a irregularly slightly elevated RPE, without hyporeflective intraretinal/subretinal fluid.[71](#opo12675-bib-0071){ref-type="ref"} Prospective studies show that eyes with a quiescent CNV have a 15.2--18.1 higher risk of becoming exudative, as compared to eyes lacking a precursor quiescent CNV.[72](#opo12675-bib-0072){ref-type="ref"}, [73](#opo12675-bib-0073){ref-type="ref"}, [74](#opo12675-bib-0074){ref-type="ref"} Whether eyes with quiescent CNV should be more often monitored or treated preventively with anti‐VEGF injections to prevent exudation is not yet clear.

![No haemorrhaging or oedema on colour fundus photograph (left) identified quiescent choroidal neovascularisation (CNV)/subclinical choroidal neovascularisation (CNV) just below the pigment epithelium as shown between the dotted lines on optical coherence tomography angiography (middle) and a double layer sign showing an irregularly slightly elevated pigment epithelium as indicated between the arrows, at the site of the quiescent CNV/subclinical CNV (indicated between the dotted lines) on optical coherence tomography (right),](OPO-40-140-g008){#opo12675-fig-0008}

Other imaging features {#opo12675-sec-0032}
----------------------

### Incomplete retinal pigment epithelium and outer retina atrophy (iRORA) {#opo12675-sec-0033}

Incomplete RPE and outer retinal atrophy (iRORA) is a feature preceding the development of complete RPE and outer retina atrophy (cRORA).[8](#opo12675-bib-0008){ref-type="ref"}, [50](#opo12675-bib-0050){ref-type="ref"} iRORA includes a discontinued hypertransmission of light below the RPE, an irregular or interrupted RPE layer, and a subsided outer plexiform layer and inner nuclear layer (*Figure* [9](#opo12675-fig-0009){ref-type="fig"} *a*).[9](#opo12675-bib-0009){ref-type="ref"} A total of 74% of the eyes that meet incomplete RORA develop complete RORA within 5 years.[50](#opo12675-bib-0050){ref-type="ref"}

![Incomplete retinal pigment epithelium atrophy and outer retina atrophy (iRORA) on optical coherence tomography as seen by irregular or interrupted RPE layer, indicated between dotted lines and a subsided outer plexiform layer and inner nuclear layer, indicated with an arrow (a), and an outer retinal tubulation on optical coherence tomography, as indicated with an arrow (b).](OPO-40-140-g009){#opo12675-fig-0009}

### Outer retinal tubulations {#opo12675-sec-0034}

Outer retinal tubulations (ORTs) can be identified on OCT as circular hyperreflective band structures in the outer nuclear layer (*Figure* [9](#opo12675-fig-0009){ref-type="fig"} *b*). They develop in response to injury as Müller cells move between the functional and dead photoreceptors. ORTs can both be found in areas of fibrosis after the development of exudative nAMD, or at the border of GA. In nAMD, eyes with ORTs often have a larger decline in visual acuity over time than those without ORTs.[75](#opo12675-bib-0075){ref-type="ref"} However, in patients with GA, ORTs at the border of the GA lesion are associated with a slower rate of GA enlargement when compared to those without ORTs.[76](#opo12675-bib-0076){ref-type="ref"}

Demographic and environmental risk factors {#opo12675-sec-0035}
==========================================

Age {#opo12675-sec-0036}
---

There are many modifiable and non‐modifiable risk factors that have been linked to increased risk of the progression of AMD. As the name already suggests, age is the most important demographic risk factor for AMD.[20](#opo12675-bib-0020){ref-type="ref"}, [21](#opo12675-bib-0021){ref-type="ref"}, [23](#opo12675-bib-0023){ref-type="ref"}, [27](#opo12675-bib-0027){ref-type="ref"}, [31](#opo12675-bib-0031){ref-type="ref"}, [32](#opo12675-bib-0032){ref-type="ref"}, [40](#opo12675-bib-0040){ref-type="ref"}, [77](#opo12675-bib-0077){ref-type="ref"}, [78](#opo12675-bib-0078){ref-type="ref"}, [79](#opo12675-bib-0079){ref-type="ref"}, [80](#opo12675-bib-0080){ref-type="ref"}, [81](#opo12675-bib-0081){ref-type="ref"}, [82](#opo12675-bib-0082){ref-type="ref"}, [83](#opo12675-bib-0083){ref-type="ref"}, [84](#opo12675-bib-0084){ref-type="ref"}, [85](#opo12675-bib-0085){ref-type="ref"}, [86](#opo12675-bib-0086){ref-type="ref"}, [87](#opo12675-bib-0087){ref-type="ref"}, [88](#opo12675-bib-0088){ref-type="ref"}, [89](#opo12675-bib-0089){ref-type="ref"}, [90](#opo12675-bib-0090){ref-type="ref"}, [91](#opo12675-bib-0091){ref-type="ref"}, [92](#opo12675-bib-0092){ref-type="ref"}, [93](#opo12675-bib-0093){ref-type="ref"}, [94](#opo12675-bib-0094){ref-type="ref"}, [95](#opo12675-bib-0095){ref-type="ref"} A recent meta‐analysis, combining data of 14 population‐based studies, showed an increase in the prevalence of early AMD from 3.5% in people aged 55--59 years up to 17.6% in people 85 years and older. For late AMD, these prevalence rates increase from 0.1% to 9.8%, respectively.[96](#opo12675-bib-0096){ref-type="ref"} Prospective studies show that age is slightly stronger associated with the progression to GA (HR 1.14--1.18, per year increase)[23](#opo12675-bib-0023){ref-type="ref"}, [40](#opo12675-bib-0040){ref-type="ref"} than to nAMD (HR 1.08, per year increase).[94](#opo12675-bib-0094){ref-type="ref"} Higher age is the main risk factor for AMD since ageing is associated with structural and functional changes of the retina that predispose the development of AMD, and contributes to the additive effects of other pathological risk factors over time.[97](#opo12675-bib-0097){ref-type="ref"}

Sex {#opo12675-sec-0037}
---

While AMD is common in males and females, some studies suggest that female sex is associated with a higher progression rate to early AMD (OR 2.2),[40](#opo12675-bib-0040){ref-type="ref"}, [85](#opo12675-bib-0085){ref-type="ref"} and late AMD (HR 1.6--2.6),[84](#opo12675-bib-0084){ref-type="ref"}, [87](#opo12675-bib-0087){ref-type="ref"}, [94](#opo12675-bib-0094){ref-type="ref"} especially nAMD (HR 1.6--2.1).[27](#opo12675-bib-0027){ref-type="ref"}, [77](#opo12675-bib-0077){ref-type="ref"}, [94](#opo12675-bib-0094){ref-type="ref"} However, other studies describe a lack of association between sex and disease progression.[20](#opo12675-bib-0020){ref-type="ref"}, [23](#opo12675-bib-0023){ref-type="ref"}, [32](#opo12675-bib-0032){ref-type="ref"}, [57](#opo12675-bib-0057){ref-type="ref"}, [78](#opo12675-bib-0078){ref-type="ref"}, [80](#opo12675-bib-0080){ref-type="ref"}, [81](#opo12675-bib-0081){ref-type="ref"}, [83](#opo12675-bib-0083){ref-type="ref"}, [86](#opo12675-bib-0086){ref-type="ref"}, [89](#opo12675-bib-0089){ref-type="ref"}, [91](#opo12675-bib-0091){ref-type="ref"}, [92](#opo12675-bib-0092){ref-type="ref"}, [93](#opo12675-bib-0093){ref-type="ref"}, [95](#opo12675-bib-0095){ref-type="ref"}, [98](#opo12675-bib-0098){ref-type="ref"} A possible explanation for these conflicting results between studies might be attributed to a difference in follow‐up and the greater life expectancy of females.[99](#opo12675-bib-0099){ref-type="ref"} However, some studies suggest that AMD progression might indeed follow different processes in females due to differences in sex hormones, such as estrogens. Estrogens may lead to favorable alterations in serum lipids and may exert antioxidant properties. Some cross‐sectional studies have found evidence of a protective effect of estrogen exposure in females. Females using hormone replacement therapy had a decreased risk of having AMD,[100](#opo12675-bib-0100){ref-type="ref"} and females who reached menopause at an earlier age had an increased risk of having AMD.[101](#opo12675-bib-0101){ref-type="ref"} However, other studies did not confirm these findings.[2](#opo12675-bib-0002){ref-type="ref"}, [102](#opo12675-bib-0102){ref-type="ref"}, [103](#opo12675-bib-0103){ref-type="ref"}, [104](#opo12675-bib-0104){ref-type="ref"}, [105](#opo12675-bib-0105){ref-type="ref"} Longitudinal analyses of prospective cohorts are required to enhance our understanding of the association between estrogen exposure and the risk of AMD.

Another hypothesis for sex‐associated differences in AMD progression may be caused by the number of X‐linked genes which may affect cellular functions in the onset and progression of AMD.[106](#opo12675-bib-0106){ref-type="ref"} No AMD‐associated variants have been identified in X‐linked genes, but epigenetic mechanisms might have a role in the pathogenesis of AMD by acting on X‐linked genes.

Smoking {#opo12675-sec-0038}
-------

Smoking is the most consistently reported modifiable risk factor for AMD and is associated with a 2--4 fold increased risk for any form of AMD,[20](#opo12675-bib-0020){ref-type="ref"}, [21](#opo12675-bib-0021){ref-type="ref"}, [31](#opo12675-bib-0031){ref-type="ref"}, [63](#opo12675-bib-0063){ref-type="ref"}, [94](#opo12675-bib-0094){ref-type="ref"} early AMD[40](#opo12675-bib-0040){ref-type="ref"}, [85](#opo12675-bib-0085){ref-type="ref"}, and late AMD[32](#opo12675-bib-0032){ref-type="ref"}, [85](#opo12675-bib-0085){ref-type="ref"}, [87](#opo12675-bib-0087){ref-type="ref"}, [91](#opo12675-bib-0091){ref-type="ref"}, [107](#opo12675-bib-0107){ref-type="ref"} including nAMD[92](#opo12675-bib-0092){ref-type="ref"} and GA,[2](#opo12675-bib-0002){ref-type="ref"}, [23](#opo12675-bib-0023){ref-type="ref"}, [92](#opo12675-bib-0092){ref-type="ref"} and is associated with a faster GA growth (0.33 mm year^−1^ in smokers compared to 0.27 mm year^−1^ in non‐smokers).[63](#opo12675-bib-0063){ref-type="ref"} Several studies have also compared pack‐years of smoking, and most of them confirmed an additive dose‐response effect.[21](#opo12675-bib-0021){ref-type="ref"}, [77](#opo12675-bib-0077){ref-type="ref"}, [84](#opo12675-bib-0084){ref-type="ref"}, [108](#opo12675-bib-0108){ref-type="ref"} Even after quitting smoking, ex‐smokers still have a modestly increased risk of disease progression compared to never‐smokers,[87](#opo12675-bib-0087){ref-type="ref"} although this association is not always found.[2](#opo12675-bib-0002){ref-type="ref"}, [57](#opo12675-bib-0057){ref-type="ref"}, [80](#opo12675-bib-0080){ref-type="ref"}, [81](#opo12675-bib-0081){ref-type="ref"}, [82](#opo12675-bib-0082){ref-type="ref"}, [86](#opo12675-bib-0086){ref-type="ref"}, [88](#opo12675-bib-0088){ref-type="ref"}, [93](#opo12675-bib-0093){ref-type="ref"}, [98](#opo12675-bib-0098){ref-type="ref"}, [109](#opo12675-bib-0109){ref-type="ref"}, [110](#opo12675-bib-0110){ref-type="ref"}, [111](#opo12675-bib-0111){ref-type="ref"} Quitting smoking reduces the risk of developing AMD and after 20 years cessation of smoking, risk probabilities of developing AMD seem to be comparable to that of non‐smokers.[112](#opo12675-bib-0112){ref-type="ref"} Cigarette smoke is known to contain toxic compounds that may have pathological effects through different biochemical pathways, including the formation of retinal oxidative stress (see section on oxidative stress factors) and inflammation in RPE cells and vascular changes in the choroidal vessels.

Body composition {#opo12675-sec-0039}
----------------

Having a higher body mass index (BMI) is found to be associated with increased probabilities of developing AMD in half of the studies,[77](#opo12675-bib-0077){ref-type="ref"}, [84](#opo12675-bib-0084){ref-type="ref"}, [86](#opo12675-bib-0086){ref-type="ref"}, [92](#opo12675-bib-0092){ref-type="ref"}, [94](#opo12675-bib-0094){ref-type="ref"}, [98](#opo12675-bib-0098){ref-type="ref"}, [110](#opo12675-bib-0110){ref-type="ref"}, [113](#opo12675-bib-0113){ref-type="ref"} while other studies found no association.[2](#opo12675-bib-0002){ref-type="ref"}, [21](#opo12675-bib-0021){ref-type="ref"}, [87](#opo12675-bib-0087){ref-type="ref"}, [88](#opo12675-bib-0088){ref-type="ref"}, [93](#opo12675-bib-0093){ref-type="ref"}, [108](#opo12675-bib-0108){ref-type="ref"}, [109](#opo12675-bib-0109){ref-type="ref"}, [111](#opo12675-bib-0111){ref-type="ref"}, [114](#opo12675-bib-0114){ref-type="ref"}, [115](#opo12675-bib-0115){ref-type="ref"}, [116](#opo12675-bib-0116){ref-type="ref"} In comparison with individuals with a normal weight (BMI 20--25), obese individuals (BMI \> 30) have an increased risk for developing late AMD (OR 1.2--2.2).[77](#opo12675-bib-0077){ref-type="ref"}, [84](#opo12675-bib-0084){ref-type="ref"}, [86](#opo12675-bib-0086){ref-type="ref"}, [91](#opo12675-bib-0091){ref-type="ref"}, [92](#opo12675-bib-0092){ref-type="ref"} Also other measurements of body weight such as waist circumference (WC) and waist‐hip ratio (WHR) have been studied and confirmed the associated between body weight and disease progression.[110](#opo12675-bib-0110){ref-type="ref"}, [113](#opo12675-bib-0113){ref-type="ref"} For example, one longitudinal population cohort found that a decrease in WHR is associated with a lower incidence rate of any form of AMD (per 3% WHR decline, OR 0.71). This effect was even more pronounced in obese patients (per 3% WHR decline, OR 0.41).[117](#opo12675-bib-0117){ref-type="ref"}

Studies have shown that pro‐inflammatory factors, such as complement components and cytokines are elevated in obese individuals. These proinflammatory factors regulate inflammation and could disturb the functions of the RPE, which contributes to the development of AMD. In addition, adipose tissue is a storage site of protective carotenoids (see section on carotenoids) and as the bodyweight increases, more carotenoids would be absorbed into adipocytes and as a consequence less of these carotenoids would be available in the macula.[118](#opo12675-bib-0118){ref-type="ref"}

Diet {#opo12675-sec-0040}
----

Diet is found to have a potential role in preventing and/or delaying the progression of AMD. High adherence to the Mediterranean diet reduces the risk of developing late AMD, which has been confirmed in two prospective cohorts,[119](#opo12675-bib-0119){ref-type="ref"}, [120](#opo12675-bib-0120){ref-type="ref"} while another prospective cohort did not find any association.[85](#opo12675-bib-0085){ref-type="ref"} The Mediterranean diet is naturally rich in antioxidants and typically characterised by high consumption of fruits, vegetables, legumes, grains and nuts, moderate consumption of fish, poultry, and dairy, and limited consumption of red meat. Olive oil rich in unsaturated fatty acids is used instead of butter and low to moderate amounts of red wine may be consumed.

In addition, other prospective studies investigating nutrition have found that the consumption of a high‐glycemic‐index diet (diet with carbohydrates that have a large and fast effect on blood glucose levels) is a risk factor for the development and progression of AMD.[121](#opo12675-bib-0121){ref-type="ref"}, [122](#opo12675-bib-0122){ref-type="ref"}

Furthermore, individual components of the diet, such as the number of specific vegetables and fruits are also thought to be protective for disease progression since they are rich in antioxidants, including vitamins and carotenoids (see section on anti‐oxidative factors). Yet, individual diet components are not often found to be associated with disease progression in prospective studies.[119](#opo12675-bib-0119){ref-type="ref"} This is partly because dietary assessment methods for these foods are sensitive to bias since they rely on the participant\'s memory and have a day‐to‐day variability. Despite these methodological problems, multiple prospective studies were still able to confirm that fish consumption reduces the risk of disease progression in AMD.[23](#opo12675-bib-0023){ref-type="ref"}, [107](#opo12675-bib-0107){ref-type="ref"}, [119](#opo12675-bib-0119){ref-type="ref"}, [123](#opo12675-bib-0123){ref-type="ref"}, [124](#opo12675-bib-0124){ref-type="ref"}, [125](#opo12675-bib-0125){ref-type="ref"}, [126](#opo12675-bib-0126){ref-type="ref"}, [127](#opo12675-bib-0127){ref-type="ref"} Consumption of 1--2 servings fish per week has an OR of 0.48--0.58 for developing late AMD over 10 years of follow‐up. Fish is known to be rich in DHA and EPA, which are protective fatty acids (see section, Fatty acids).

Physical activity {#opo12675-sec-0041}
-----------------

Regular exercise is thought to increase antioxidant enzyme activity and therefore physical activity may influence the progression of AMD. A few studies support the positive impact of physical activity on the progression of AMD, and physical activity is associated with lower odds of both early and late AMD.[85](#opo12675-bib-0085){ref-type="ref"}, [114](#opo12675-bib-0114){ref-type="ref"}, [116](#opo12675-bib-0116){ref-type="ref"}, [125](#opo12675-bib-0125){ref-type="ref"}, [128](#opo12675-bib-0128){ref-type="ref"} However, precise quantification of physical activity is difficult and therefore this factor is not suitable to use as a variable to predict AMD progression.[93](#opo12675-bib-0093){ref-type="ref"}, [111](#opo12675-bib-0111){ref-type="ref"}, [129](#opo12675-bib-0129){ref-type="ref"} Nevertheless, a small‐to‐moderate amount of physical activity should be advised to patients to confer retinal health benefit.

Education {#opo12675-sec-0042}
---------

Education levels seem to be inversely related with the development of AMD in some longitudinal population studies, in which having an education level of high school or higher is associated with a lower risk for early AMD (OR 0.86)[82](#opo12675-bib-0082){ref-type="ref"} and late AMD (OR 0.57--0.73).[77](#opo12675-bib-0077){ref-type="ref"}, [87](#opo12675-bib-0087){ref-type="ref"}, [98](#opo12675-bib-0098){ref-type="ref"} In smaller cohort studies, this association is not always found.[84](#opo12675-bib-0084){ref-type="ref"}, [86](#opo12675-bib-0086){ref-type="ref"}, [91](#opo12675-bib-0091){ref-type="ref"}, [92](#opo12675-bib-0092){ref-type="ref"}, [93](#opo12675-bib-0093){ref-type="ref"}, [111](#opo12675-bib-0111){ref-type="ref"} Education itself is unlikely to be a direct risk factor, but rather a surrogate for other risk factors that are associated with a lower education level, including smoking, poor nutrition and less use of eye care services.

Sunlight exposure {#opo12675-sec-0043}
-----------------

Sunlight exposure is thought to result in more oxidative stress in the retina, causing the development of AMD. However, the quantification of the total amount of sunlight exposure is difficult to determine and therefore not often found to be associated with disease progression.[77](#opo12675-bib-0077){ref-type="ref"}, [130](#opo12675-bib-0130){ref-type="ref"}, [131](#opo12675-bib-0131){ref-type="ref"} Nevertheless, sunglass protection should be advised to reduce retinal damage caused by sunlight exposure.

Ethnicity {#opo12675-sec-0044}
---------

Multi‐ethnic studies show difference prevalence rates of any form of AMD between ethnic groups (2.4% Africans, 4.2% Hispanics, 4.6% Chinese, 5.4% Caucasians).[77](#opo12675-bib-0077){ref-type="ref"}, [132](#opo12675-bib-0132){ref-type="ref"}, [133](#opo12675-bib-0133){ref-type="ref"} Some hypothesise that the increased melanin in RPE cells of Africans may act as free radical scavenger or as a filter for ultraviolet radiation, which protects the RPE cells and Bruch\'s membrane, reducing the risk of AMD development or disease progression.[134](#opo12675-bib-0134){ref-type="ref"} In addition, nAMD seems to be more common in the Chinese population compared to Caucasians (OR 4.3).[132](#opo12675-bib-0132){ref-type="ref"} One possibility for this difference is that in some of these individuals, polypoidal choroidal vasculopathy (PCV) or a CNV caused by myopic maculopathy (MM) may be diagnosed. These retinal diseases mimic nAMD but without signs of drusen or RPE changes. Both retinal diseases are more common in the Asian population.[135](#opo12675-bib-0135){ref-type="ref"} Finally, it is possible that the differences in phenotypic characteristics of AMD differ between ethnic groups, perhaps related to racial differences in susceptibility genes for AMD.[136](#opo12675-bib-0136){ref-type="ref"}

Comorbidity {#opo12675-sec-0045}
-----------

### Cataract {#opo12675-sec-0046}

Several large epidemiological studies have found an increased association between the development of cataract, cataract surgery and late AMD (both GA and nAMD),[137](#opo12675-bib-0137){ref-type="ref"}, [138](#opo12675-bib-0138){ref-type="ref"}, [139](#opo12675-bib-0139){ref-type="ref"} whereas others have demonstrated no association.[57](#opo12675-bib-0057){ref-type="ref"}, [77](#opo12675-bib-0077){ref-type="ref"}, [140](#opo12675-bib-0140){ref-type="ref"}, [141](#opo12675-bib-0141){ref-type="ref"} Some hypothesise that cataract surgery may increase the incidence of AMD and accelerate disease progression, possibly due to the induction of inflammatory reactions during and after surgery, and from increased exposure to ultraviolet light on the retina afterward.[142](#opo12675-bib-0142){ref-type="ref"} Others believe that cataract and AMD share environmental risk factors such as age, smoking, obesity, hypertension and sunlight exposure, and consequently, individuals who have had cataract surgery are automatically at higher risk for developing AMD as well.[143](#opo12675-bib-0143){ref-type="ref"} Besides, cataract surgery may even be beneficial for AMD patients in both visual acuity and quality‐of‐life parameters.[144](#opo12675-bib-0144){ref-type="ref"} Nevertheless, the association of cataract with AMD and the effect of cataract surgery remains a topic of active debate that is often revisited.

### Hypertension {#opo12675-sec-0047}

The possible involvement of hypertension in AMD has been well covered in literature,[21](#opo12675-bib-0021){ref-type="ref"}, [88](#opo12675-bib-0088){ref-type="ref"}, [95](#opo12675-bib-0095){ref-type="ref"}, [116](#opo12675-bib-0116){ref-type="ref"}, [145](#opo12675-bib-0145){ref-type="ref"} but is not always found to be a risk factor for AMD.[2](#opo12675-bib-0002){ref-type="ref"}, [40](#opo12675-bib-0040){ref-type="ref"}, [57](#opo12675-bib-0057){ref-type="ref"}, [77](#opo12675-bib-0077){ref-type="ref"}, [93](#opo12675-bib-0093){ref-type="ref"}, [94](#opo12675-bib-0094){ref-type="ref"}, [98](#opo12675-bib-0098){ref-type="ref"}, [108](#opo12675-bib-0108){ref-type="ref"}, [111](#opo12675-bib-0111){ref-type="ref"}, [115](#opo12675-bib-0115){ref-type="ref"}, [146](#opo12675-bib-0146){ref-type="ref"} High blood pressure is shown to be associated with lower choroidal blood flow and disturbed vascular homeostasis.[147](#opo12675-bib-0147){ref-type="ref"} Nevertheless, antihypertensive medication is not proven to have a positive effect on AMD. Although hypertension seems to play a role, it is unlikely to be a major contributor to the incidence and progression of AMD.

### Chronic kidney disease {#opo12675-sec-0048}

The association between chronic kidney disease has been reported in some studies, but evidence have been conflicting.[95](#opo12675-bib-0095){ref-type="ref"}, [148](#opo12675-bib-0148){ref-type="ref"}, [149](#opo12675-bib-0149){ref-type="ref"} One prospective cohort showed that, only in individuals older than 65 years, a decrease in the estimated glomerular filtration rate (eGFR) is associated with an increased probability of developing early AMD over fiveyears (per eGFR decrease of 10 mL min^−1^ 1.73 m^−2^, OR 1.3).[150](#opo12675-bib-0150){ref-type="ref"} In addition, cystatin C, a serum biomarker for kidney function, has also been associated with the development of early AMD and nAMD.[149](#opo12675-bib-0149){ref-type="ref"} Whether the association between AMD and chronic kidney disease (CKD) reflects a common causal pathway or shared risk factors such as age, chronic inflammation, and variants in the *CFH* gene, requires additional investigation.[148](#opo12675-bib-0148){ref-type="ref"}

### Hyperthyroidism {#opo12675-sec-0049}

Longitudinal population studies show that thyroid disease causing hyperthyroidism has been implicated as a risk factor for developing late AMD[151](#opo12675-bib-0151){ref-type="ref"}, [152](#opo12675-bib-0152){ref-type="ref"}, [153](#opo12675-bib-0153){ref-type="ref"} . Serum free thyroxine (FT4) levels are associated with increased risk of developing AMD (FT4 increase per pmol L^−1^, HR 1.04)[153](#opo12675-bib-0153){ref-type="ref"}, while serum thyroid‐stimulating hormone (TSH) is not.[151](#opo12675-bib-0151){ref-type="ref"}, [153](#opo12675-bib-0153){ref-type="ref"} It is suggested that hyperthyroidism can accelerate the basal metabolic rate and oxidative metabolism by induction of mitochondrial enzymes, which may induce oxidative stress.[154](#opo12675-bib-0154){ref-type="ref"} Also, there is evidence that thyroid hormones may adversely influence RPE cells, causing degeneration of photoreceptors.[155](#opo12675-bib-0155){ref-type="ref"}, [156](#opo12675-bib-0156){ref-type="ref"}

### Diabetes {#opo12675-sec-0050}

Diabetes is a major concern in ophthalmic care. Whether it also contributes to the development of AMD remains unclear. Several studies present positive correlations between diabetes and the development of AMD,[77](#opo12675-bib-0077){ref-type="ref"}, [95](#opo12675-bib-0095){ref-type="ref"} but most studies show no effect.[2](#opo12675-bib-0002){ref-type="ref"}, [94](#opo12675-bib-0094){ref-type="ref"}, [108](#opo12675-bib-0108){ref-type="ref"}, [111](#opo12675-bib-0111){ref-type="ref"}, [115](#opo12675-bib-0115){ref-type="ref"}, [146](#opo12675-bib-0146){ref-type="ref"} Hyperglycemia and dyslipidemia in diabetic patients is thought to disturb the homeostasis of the retina by inducing inflammatory responses in retinal tissue, including oxidative stress.[157](#opo12675-bib-0157){ref-type="ref"} However, diabetes itself is probably not a strong predictor for the development of AMD.

### Alzheimer\'s disease (AD) {#opo12675-sec-0051}

Studies have found several clinical and pathologic similarities between AD and AMD. First of all, ageing is a major risk factor for both multifactorial degenerative disorders.[158](#opo12675-bib-0158){ref-type="ref"} Secondly, extracellular amyloid β‐peptide deposition, the primary pathologic hallmark of AD, is also a component of drusen in AMD.[159](#opo12675-bib-0159){ref-type="ref"} Furthermore, both diseases involve several isoforms encoded by different alleles of the apolipoprotein E (*APOE*) gene. Interestingly, while the APOE Ԑ2 and Ԑ4 isoforms, encoded by two *APOE* alleles, are associated with a decreased and increased risk for AD respectively, opposite directions are reported for AMD (see section on lipid metabolism genes).[160](#opo12675-bib-0160){ref-type="ref"}, [161](#opo12675-bib-0161){ref-type="ref"} In literature, the association between AD and AMD remains inconclusive.[162](#opo12675-bib-0162){ref-type="ref"}, [163](#opo12675-bib-0163){ref-type="ref"} Even if AD and AMD share some similarities in immune and inflammatory degenerative mechanisms, these diseases are probably not directly associated.

### Parkinson's disease (PD) {#opo12675-sec-0052}

Parkinson's disease is a progressive neurodegenerative disorder that results in the loss of dopaminergic neurons in the substantia nigra and causes motor abnormalities including bradykinesia, resting tremor and imbalance. A recent epidemiologic study showed that patients with PD treated with levodopa less often developed AMD (OR 0.78) and at a later age (mean age of onset 79 years) compared to untreated patients (mean age of onset 71 years).[164](#opo12675-bib-0164){ref-type="ref"} Levodopa is shown to stimulate the GRP143 receptor which decreases the release of VEGF and exosomes with inflammatory factors from RPE cells.[165](#opo12675-bib-0165){ref-type="ref"} Currently, clinical trials are investigating whether treatment with levodopa may indeed reduce the inflammatory reaction of the retina and slow down disease progression in AMD. Although it is not likely that PD and AMD are directly associated, both neurodegenerative diseases share probably some underlying pathophysiological features.

Genetic risk factors {#opo12675-sec-0053}
====================

Genetic factors are known to play an important role in the development of AMD and genetic studies have contributed significantly to our knowledge on AMD pathology. To date, more than half of the genomic heritability can be explained by both common and rare genetic variants in 34 genetic loci, which are mostly involved in the complement system, extracellular matrix remodeling, and lipid metabolism.[166](#opo12675-bib-0166){ref-type="ref"} *Table* [1](#opo12675-tbl-0001){ref-type="table"} and Table [S3](#opo12675-sup-0001){ref-type="supplementary-material"} show an overview of the top hits in the 34 AMD associated loci, as identified in the original Genome Wide Association Study (GWAS) of 2016. Variants of other studies were also included when they were in high linkage disequilibrium (LD) with the AMD‐associated variants of the original discovery GWAS, as referred in the subscript. Of all discovered AMD‐associated variants, a few have also been associated with disease progression in a recent GWAS on progression to late stage AMD,[167](#opo12675-bib-0167){ref-type="ref"} and in several prospective cohort studies.

###### 

Summary overview of the top hits in the 34 age‐related macular degeneration (AMD) associated loci, as identified in the case‐control Genome Wide Association Study (GWAS) from the International AMD Genomics Consortium, and their association with disease progression as described in the GWAS of the Age‐Related Eye Disease Study (AREDS), and several prospective cohort studies

                                                                          Case‐control GWAS[‡](#opo12675-note-0004){ref-type="fn"} ^,^ [166](#opo12675-bib-0166){ref-type="ref"}   GWAS on progression[§](#opo12675-note-0005){ref-type="fn"} ^,^ [167](#opo12675-bib-0167){ref-type="ref"}   Prospective studies on progression[¶](#opo12675-note-0006){ref-type="fn"}             
  ------------------ ---------------------------------------------------- -------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------- ---- ---- ----
  Locus name         Index variant                                                                                                                                                                                                                                                                                                                                                   
  *CFH*              rs10922109[†](#opo12675-note-0003){ref-type="fn"}    ↓                                                                                                        --                                                                                                         --                                                                          ↓    --   --
  *CFH*              rs570618[†](#opo12675-note-0003){ref-type="fn"}      ↑                                                                                                        ↑                                                                                                          ↑                                                                           ↑    ↑    --
  *COL4A3*           rs11884770                                           ↓                                                                                                        --                                                                                                         --                                                                          --   --   --
  *ADAMTS9‐AS2*      rs62247658[†](#opo12675-note-0003){ref-type="fn"}    ↑                                                                                                        --                                                                                                         --                                                                          --   --   --
  *COL8A1*           rs140647181                                          ↑                                                                                                        --                                                                                                         --                                                                          --   --   --
  *CFI*              rs10033900                                           ↑                                                                                                        --                                                                                                         --                                                                          --   ↑    --
  *C9*               rs62358361                                           ↑                                                                                                        --                                                                                                         --                                                                          --   --   --
  *PRLR/SPEF2*       rs114092250                                          ↓                                                                                                        --                                                                                                         --                                                                          --   --   --
  *C2/CFB/SKIV2L*    rs116503776[†](#opo12675-note-0003){ref-type="fn"}   ↓                                                                                                        ↓                                                                                                          --                                                                          ↓    --   --
  *VEGFA*            rs943080                                             ↓                                                                                                        --                                                                                                         --                                                                          --   --   --
  *KMT2E/SRPK2*      rs1142                                               ↑                                                                                                        --                                                                                                         --                                                                          --   --   --
  *PILRB/PILRA*      rs7803454                                            ↑                                                                                                        --                                                                                                         --                                                                          --   --   --
  *TNFRSF10A*        rs79037040                                           ↓                                                                                                        --                                                                                                         --                                                                          --   --   --
  *MIR6130/RORB*     rs10781182                                           ↑                                                                                                        --                                                                                                         --                                                                          --   --   --
  *TRPM3*            rs71507014                                           ↑                                                                                                        --                                                                                                         --                                                                          --   --   --
  *TGFBR1*           rs1626340[†](#opo12675-note-0003){ref-type="fn"}     ↓                                                                                                        --                                                                                                         --                                                                          --   --   --
  *ABCA1*            rs2740488[†](#opo12675-note-0003){ref-type="fn"}     ↓                                                                                                        --                                                                                                         ↓                                                                           --   --   --
  *ARHGAP21*         rs12357257                                           ↑                                                                                                        --                                                                                                         --                                                                          --   --   --
  *ARMS2/HTRA1*      rs3750846[†](#opo12675-note-0003){ref-type="fn"}     ↑                                                                                                        ↑                                                                                                          ↑                                                                           ↑    ↑    ↑
  *RDH5/CD63*        rs3138141                                            ↑                                                                                                        --                                                                                                         --                                                                          --   --   --
  *ACAD10*           rs61941274                                           ↑                                                                                                        --                                                                                                         --                                                                          ↑    --   --
  *B3GALTL*          rs9564692                                            ↓                                                                                                        --                                                                                                         --                                                                          --   --   --
  *RAD51*            rs61985136[†](#opo12675-note-0003){ref-type="fn"}    ↓                                                                                                        --                                                                                                         --                                                                          ↓    --   --
  *LIPC*             rs2043085                                            ↓                                                                                                        --                                                                                                         --                                                                          ↓    ↓    --
  *CETP*             rs5817082[†](#opo12675-note-0003){ref-type="fn"}     ↓                                                                                                        --                                                                                                         ↓                                                                           --   --   --
  *CTRB2/CTRB1*      rs72802342                                           ↓                                                                                                        --                                                                                                         --                                                                          ↓    ↓    --
  *TMEM97/VTN*       rs11080055                                           ↓                                                                                                        --                                                                                                         --                                                                          --   --   --
  *NPLOC4/TSPAN10*   rs6565597                                            ↑                                                                                                        --                                                                                                         --                                                                          --   --   --
  *C3*               rs2230199                                            ↑                                                                                                        ↑                                                                                                          --                                                                          ↑    ↑    ↓
  *CNN2*             rs67538026                                           ↓                                                                                                        --                                                                                                         --                                                                          --   --   --
  *APOE*             rs429358                                             ↓                                                                                                        --                                                                                                         --                                                                          --   --   --
  *MMP9*             rs142450006                                          ↓                                                                                                        --                                                                                                         --                                                                          ↓    --   --
  *C20orf85*         rs201459901                                          ↓                                                                                                        --                                                                                                         --                                                                          --   --   --
  *SYN3/TIMP3*       rs5754227                                            ↓                                                                                                        --                                                                                                         --                                                                          --   --   --
  *SLC16A8*          rs8135665                                            ↑                                                                                                        --                                                                                                         --                                                                          --   --   --

↑, minor allele is a risk factor; ↓, minor allele is a protective factor; AMD, age‐related macular degeneration; AREDS, Age‐Related Eye Disease Study; GA, Geographic atrophy; GWAS, Genome Wide Association Study; nAMD, neovascular age‐related macular degeneration.

The following variants were also included since they are in high LD (*R* ^2^ \> 0.80) with the AMD‐associated variants of the original discovery GWAS of 2016: *ADAMTS9‐AS2:* rs6795735 for rs62247658 (*R* ^2^ = 0.984), *ARMS2/HTRA1:* rs10490924 for rs3750846 (*R* ^2^ = 1.0), *C2/CFB/SKIV2L:* rs429608 for rs116503776 (*R* ^2^ = 1.0), *CFH*: rs1410996 for rs10922109 (*R* ^2^ = 1.0), *CFH*: rs1061170 for rs570618 (*R* ^2^ = 1.0), *RAD51B*: rs8017304 for rs61985136 (*R* ^2^ = 1.0), *TGFBR1*: rs334353 for rs1626340 (*R* ^2^ = 0.855), *CETP*: rs1864163 for rs5817082 (*R* ^2^ = 0.975), *ABCA1*: rs1883025 for rs2740488 (*R* ^2^ = 0.941).

Original discovery GWAS, based on case‐control study from the International AMD Genomics Consortium using 33 976 participants (no follow‐up).

GWAS on AMD progression, based on a prospective data from the AREDS study using 2721 participants (10 years follow‐up).

Table [S3](#opo12675-sup-0001){ref-type="supplementary-material"} provides detailed information on the prospective studies included in this overview.

John Wiley & Sons, Ltd

Complement genes {#opo12675-sec-0054}
----------------

In 2005, several research groups identified a common variant (rs1061170) in the complement factor H (*CFH*) gene which had a strong effect on the risk of AMD. This variant is in perfect LD (*R* ^2^ = 1.0) with the rs570618 variant in the original discovery GWAS of 2016. Multiple prospective studies have confirmed that the minor allele of this variant is a risk allele for the incidence of early AMD (HR 1.2--2.3),[40](#opo12675-bib-0040){ref-type="ref"}, [92](#opo12675-bib-0092){ref-type="ref"}, [107](#opo12675-bib-0107){ref-type="ref"}, [168](#opo12675-bib-0168){ref-type="ref"}, [169](#opo12675-bib-0169){ref-type="ref"} as well as for the progression to nAMD (HR 1.48--2.5)[92](#opo12675-bib-0092){ref-type="ref"}, [170](#opo12675-bib-0170){ref-type="ref"} and GA (HR 1.38--3.65).[23](#opo12675-bib-0023){ref-type="ref"}, [86](#opo12675-bib-0086){ref-type="ref"}, [92](#opo12675-bib-0092){ref-type="ref"}, [171](#opo12675-bib-0171){ref-type="ref"} Another common variant in the *CFH* gene is the rs10922109 variant, of which the minor allele is confirmed to be a protective allele for the progression to late stage AMD (HR 0.43).[167](#opo12675-bib-0167){ref-type="ref"}, [170](#opo12675-bib-0170){ref-type="ref"} However, both variants in the *CFH* gene have not yet been confirmed to be also associated with a more rapid GA enlargement in two prospective studies.[63](#opo12675-bib-0063){ref-type="ref"}, [172](#opo12675-bib-0172){ref-type="ref"}

Variants in other complement loci, including *C2/CFB*, *CFI,* and *C3* have also found to be associated with disease progression in several studies. The minor allele of the rs116503776 variant in *C2/CFB* is a protective allele for disease progression to late stage AMD (HR 0.56)[167](#opo12675-bib-0167){ref-type="ref"}, [173](#opo12675-bib-0173){ref-type="ref"}; the minor allele of the rs10033900 variant in *CFI* is a risk allele for AMD, but has only been confirmed to be associated with disease progression to GA (HR 1.19)[92](#opo12675-bib-0092){ref-type="ref"}; and the minor allele of the rs2230199 variant in *C3* is a risk allele for AMD and confirmed to be a risk factor for the incidence of early AMD (HR 1.22),[92](#opo12675-bib-0092){ref-type="ref"} and progression to nAMD (HR 1.25)[92](#opo12675-bib-0092){ref-type="ref"} and GA (HR 1.26).[86](#opo12675-bib-0086){ref-type="ref"}, [92](#opo12675-bib-0092){ref-type="ref"} Interestingly, when GA had developed, the minor allele of the rs2230199 variant in *C3* was a protective factor for GA growth (the wildtype, heterozygous and homozygous combination had progression rates of 0.30, 0.27 and 0.15 mm year^−1^, respectively), which was later confirmed in another cohort.[63](#opo12675-bib-0063){ref-type="ref"}, [172](#opo12675-bib-0172){ref-type="ref"} The authors hypothesised that AMD‐associated variants may have differential effects at different disease stages.

The *ARMS2/HTRA1* genes {#opo12675-sec-0055}
-----------------------

The common rs10490924 variant near the *Age‐related maculopathy susceptibility 2* and *high‐temperature requirement A serine peptidase 1* (*ARMS2*/*HTRA1*) genes has also a strong effect on the risk of AMD and was also identified in the first genetic AMD studies. This common variant is in perfect LD (*R* ^2^ = 1.0) with the rs3750846 variant in the original discovery GWAS of 2016. Several prospective studies have confirmed that the minor allele of this variant is a risk factor for the incidence of early AMD (OR 1.36), [40](#opo12675-bib-0040){ref-type="ref"}, [92](#opo12675-bib-0092){ref-type="ref"} and progression to nAMD (HR 1.4--2.8) [92](#opo12675-bib-0092){ref-type="ref"}, [170](#opo12675-bib-0170){ref-type="ref"}, [171](#opo12675-bib-0171){ref-type="ref"}, [173](#opo12675-bib-0173){ref-type="ref"} and GA (HR 1.4--3.3), [23](#opo12675-bib-0023){ref-type="ref"}, [79](#opo12675-bib-0079){ref-type="ref"}, [86](#opo12675-bib-0086){ref-type="ref"}, [92](#opo12675-bib-0092){ref-type="ref"}, [170](#opo12675-bib-0170){ref-type="ref"}, [171](#opo12675-bib-0171){ref-type="ref"} and increased GA growth (the wildtype, heterozygous and homozygous combination had progression rates of 0.23, 0.30 and 0.32 mm year^−1^, respectively).[63](#opo12675-bib-0063){ref-type="ref"}, [172](#opo12675-bib-0172){ref-type="ref"} Functional studies suggest that the *ARMS2* gene may encode a protein which has a function in the mitochondrial outer membrane of the retina, while other reports suggest that it encodes an extracellular protein.[174](#opo12675-bib-0174){ref-type="ref"}, [175](#opo12675-bib-0175){ref-type="ref"} The *HTRA1* gene encodes a heat shock serine protease and regulates TGF‐β signalling, which is involved in regulating extracellular matrix deposition and angiogenesis.[176](#opo12675-bib-0176){ref-type="ref"}, [177](#opo12675-bib-0177){ref-type="ref"} However, the exact function of the *ARMS2/HTRA1* genes and how either or both genes are related to the pathophysiology of AMD is still not fully understood.

Lipid metabolism genes {#opo12675-sec-0056}
----------------------

Genes encoding proteins of the lipid metabolism are also involved in the pathogenesis of AMD, and are probably involved in the formation of drusen.[178](#opo12675-bib-0178){ref-type="ref"} Some of the AMD‐associated variants in lipid metabolism genes found in the case‐control GWAS of 2016 are also confirmed with disease progression. For example, the minor allele of the rs2740488 variant in *ABCA1* and minor allele of the rs5817082 variant in *CETP* are both confirmed to be protective alleles for the incidence of early AMD (OR 0.77--0.82, and OR 0.87 respectively). [92](#opo12675-bib-0092){ref-type="ref"}, [168](#opo12675-bib-0168){ref-type="ref"}, [179](#opo12675-bib-0179){ref-type="ref"} In the *LIPC* gene, the minor allele of the rs2043085 variant, is a protective allele for the progression towards late AMD (HR 0.83).[92](#opo12675-bib-0092){ref-type="ref"}, [167](#opo12675-bib-0167){ref-type="ref"}

Another gene involved in lipid metabolism is the *APOE* gene, which is known to be polymorphic. Variants in the *APOE* gene at amino acid positions 112 (rs429358) and 158 (rs7412) determine three major isoforms: the Ԑ2 isoform (112C, 158C), the most common Ԑ3 isoform (112C, 158R) and the Ԑ4 isoform (112R, 158R).

Studies show that the *APOE* Ԑ4 isoform is associated with an increased risk of Alzheimer's disease and the *APOE* Ԑ2 isoform is associated with a decreased risk of Alzheimer's disease. Interestingly these two isoforms have an opposite effect in AMD: the *APOE* Ԑ4 isoform is associated with a decreased risk of AMD, and there is a trend for the *APOE* Ԑ2 isoform to be associated with an increased risk of developing AMD. [160](#opo12675-bib-0160){ref-type="ref"}, [161](#opo12675-bib-0161){ref-type="ref"} However, these *APOE* isoforms and other AMD‐associated variants in the *APOE* gene have not yet been investigated with AMD disease progression in prospective cohort studies.

Other genes {#opo12675-sec-0057}
-----------

Other variants that were identified in the original discovery GWAS of 2016, and confirmed to be associated with disease progression in AMD include rs61985136 in *RAD541B* and rs72802342 in *CTRB2/CTRB1*.[167](#opo12675-bib-0167){ref-type="ref"}, [170](#opo12675-bib-0170){ref-type="ref"} Interestingly, a recent GWAS on disease progression in AMD showed that the minor allele of the rs142450006 variant near *MMP9* was associated with progression to nAMD (HR 0.66) but not with GA.[167](#opo12675-bib-0167){ref-type="ref"} This finding was also found previously in the original discovery GWAS.[166](#opo12675-bib-0166){ref-type="ref"} In addition, the rs58978565 variant near *TNR* and the rs28368872 variant near *ATF7IP2* are associated with disease progression to nAMD but not GA.[167](#opo12675-bib-0167){ref-type="ref"} These variants were not previously found in the original discovery GWAS. Larger genome‐wide association studies with prospective data are needed to investigate whether some variants are mainly involved in a specific AMD disease stage (early AMD, nAMD or GA) and whether variants can influence the progression speed of the disease.

Rare variants {#opo12675-sec-0058}
-------------

Several studies support a role for rare variants in the pathogenesis of AMD.[166](#opo12675-bib-0166){ref-type="ref"} It has been suggested that AMD in densely affected families are likely to be caused by rare, highly penetrant variants in genes of the complement system as *C3*, *C9*, *CFH,* and *CFI*.[180](#opo12675-bib-0180){ref-type="ref"} Since some of these rare variants have been associated with an earlier age of onset, patients carrying such variants may develop late AMD at an earlier age, causing many more years of substantial vision loss.[181](#opo12675-bib-0181){ref-type="ref"}, [182](#opo12675-bib-0182){ref-type="ref"} For an accurate risk assessment, it is therefore important that genetic tests for AMD are designed to also detect rare coding variants in these genes. However, there are currently no prospective cohort studies investigating the association between rare variants and disease progression in AMD.

Molecular risk factors {#opo12675-sec-0059}
======================

Angiogenic factors {#opo12675-sec-0060}
------------------

Angiogenic factors, including vascular endothelial growth factor (VEGF), pigment epithelium derived factor (PEDF) and transforming growth factor beta (TGF‐β) have been extensively investigated in case‐control studies.[183](#opo12675-bib-0183){ref-type="ref"} VEGF is a hypoxia‐driven signal which induces the formation of new blood vessels and is currently the most important target in the treatment of nAMD to restore and/or maintain vision. PEDF is produced by RPE cells and has anti‐angiogenic properties, opposing the effects of VEGF, and supplementing with PEDF has been proposed for the treatment of nAMD.[184](#opo12675-bib-0184){ref-type="ref"} TGF‐β is found to increase the expression of VEGF and is therefore also implicated as an angiogenic factor.[185](#opo12675-bib-0185){ref-type="ref"} Cross‐sectional studies found conflicting results whether measurements of systemic and local angiogenic factors differ between AMD patients and controls.[183](#opo12675-bib-0183){ref-type="ref"} Currently, there are no prospective cohorts that have measured angiogenic factors to predict disease progression in AMD.

Oxidative stress factors {#opo12675-sec-0061}
------------------------

Increased oxidative stress is thought to be one of the underlying factors in the occurrence of AMD.

Oxidative stress reflects an imbalance between the manifestation of reactive oxygen species (ROS) and reactive nitrogen species (RNS) that damage components of cells, and the biological ability to detoxify these reactive intermediates to maintain oxidant homeostasis.[186](#opo12675-bib-0186){ref-type="ref"} The eye, especially the macula, is susceptible to oxidative stress because of its high metabolic activity and its high content of polyunsaturated fatty acids (PUFAs) in photoreceptors, which are prone to oxidation. Several case‐control studies have found evidence of elevated products of oxidative stress in AMD patients,[183](#opo12675-bib-0183){ref-type="ref"} however prospective studies investigating a correlation with AMD progression are limited.

Malondialdehyde (MDA) is a reactive carbonyl compound that originates from the oxidation of PUFAs. Case‐control studies have consistently observed increased systemic levels of MDA in AMD patients compared to controls.[183](#opo12675-bib-0183){ref-type="ref"} However, there are currently no prospective studies that have investigated MDA levels and disease progression in AMD.

Another product of oxidative stress is the oxidation of low‐density lipoproteins (LDL) forming oxidized LDL (ox‐LDL). LDL are lipoproteins (see section Lipoproteins) that are an easy target for oxidation by free radicals. While some cross‐sectional studies show increased levels of systemic ox‐LDL in AMD patients,[183](#opo12675-bib-0183){ref-type="ref"} only two prospective cohorts have investigated the relationship between systemic ox‐LDL and disease progression and found no correlation.[83](#opo12675-bib-0083){ref-type="ref"}, [146](#opo12675-bib-0146){ref-type="ref"}

Several case‐control studies show a relation between AMD and toxic trace elements, such as cadmium, lead, and mercury.[183](#opo12675-bib-0183){ref-type="ref"} These toxic trace‐elements are thought to induce oxidative stress and the production of inflammatory cytokines. In addition, some trace‐elements share numerous binding sites with other anti‐oxidative trace‐elements such as zinc (see section Zinc). Of all toxic trace‐elements, cadmium has drawn considerable attention since some studies showed that cadmium levels may be related to AMD pathogenesis, especially in the smoking population.[187](#opo12675-bib-0187){ref-type="ref"} However, there are currently no prospective studies investigating the potential usage of measuring toxic trace‐elements to predict disease progression in AMD.

Anti‐oxidative factors {#opo12675-sec-0062}
----------------------

Antioxidants, including vitamins, carotenoids and essential trace elements such as zinc, both enhance the clearance and prevent the formation of ROS and RNS, reducing the damage in retinal cells caused by oxidative stress.[188](#opo12675-bib-0188){ref-type="ref"} Several studies hypothesise that the antioxidant capacity in AMD patients might be impaired, and a decreased antioxidant capacity might be associated with both disease onset and progression. Table [S4](#opo12675-sup-0001){ref-type="supplementary-material"} shows an overview of all prospective studies analysing systemic anti‐oxidative factors and their association with the development of early and late AMD. Of note, most prospective studies investigating vitamins and carotenoids have estimated the systemic levels based on food frequency questionnaires and only a minority of the studies have measured systemic blood levels.[189](#opo12675-bib-0189){ref-type="ref"}, [190](#opo12675-bib-0190){ref-type="ref"}

### Vitamins {#opo12675-sec-0063}

Vitamin C protects against oxidative stress‐induced cellular damage by scavenging ROS and mediating reactivation of vitamin E. The idea that vitamin C may be protective was primarily based on a series of animal studies, which showed an association between vitamin C and a reduction of light‐induced damage in rat retinas.[191](#opo12675-bib-0191){ref-type="ref"} However, most prospective studies investigating the relationship between dietary intake of vitamin C and the onset and progression of AMD have shown no association.[109](#opo12675-bib-0109){ref-type="ref"}, [192](#opo12675-bib-0192){ref-type="ref"}, [193](#opo12675-bib-0193){ref-type="ref"}, [194](#opo12675-bib-0194){ref-type="ref"} Surprisingly, one longitudinal study even suggested that higher dietary vitamin C intake and supplementation could increase the risk for developing early AMD.[195](#opo12675-bib-0195){ref-type="ref"} The investigators could not explain this finding on biological grounds, nor attribute it to a measurement error or bias. Furthermore, one longitudinal population cohort measured systemic vitamin C levels and found no association with the incidence of AMD over two year follow‐up.[189](#opo12675-bib-0189){ref-type="ref"} Thus, although vitamin C is a potent antioxidant, results of prospective studies are not conclusive whether vitamin C status alone is also associated with the onset or progression of AMD.

Vitamin E is a lipophilic antioxidant in the plasma membrane of RPE cells and photoreceptors, and prevents lipid peroxidation. Prospective cohorts investigating the relationship between dietary intake of vitamin E and the risk of AMD are inconsistent. Two longitudinal population studies show a reduced risk of developing AMD when consuming a higher dietary intake of vitamin E,[192](#opo12675-bib-0192){ref-type="ref"}, [194](#opo12675-bib-0194){ref-type="ref"} while two other studies found no association.[109](#opo12675-bib-0109){ref-type="ref"}, [193](#opo12675-bib-0193){ref-type="ref"} One study even found an increased risk for GA in those consuming higher amounts of dietary vitamin E.[196](#opo12675-bib-0196){ref-type="ref"} Currently, there is only one longitudinal population study which measured systemic levels of vitamin E. This study showed that higher systemic levels of vitamin E reduce the risk of developing AMD over two years.[189](#opo12675-bib-0189){ref-type="ref"} Further studies are needed to elucidate the role of vitamin E in AMD progression.

Vitamin A is a cofactor in photoreceptors to form rhodopsin, which is a protein involved in the visual phototransduction. Dietary intake of vitamin A has not been associated with the onset of AMD in four longitudinal population studies.[192](#opo12675-bib-0192){ref-type="ref"}, [194](#opo12675-bib-0194){ref-type="ref"}, [195](#opo12675-bib-0195){ref-type="ref"}, [196](#opo12675-bib-0196){ref-type="ref"} Also systemic levels of vitamin A showed no relation with the development of AMD over two years in one longitudinal population study.[189](#opo12675-bib-0189){ref-type="ref"} However, precursors of vitamin A, such as carotenes (see section Carotenoids) are more often investigated.

B vitamins, such as vitamin B9 (folate) and B12 (cobalamin) are essential cofactors to convert homocysteine into methionine. Homocysteine is an amino acid that is susceptible to oxidation and thought to induce vascular endothelial dysfunction in nAMD.[197](#opo12675-bib-0197){ref-type="ref"} There is only one longitudinal population study that investigated the association of dietary vitamin B9 and vitamin B12 intake with the development of GA, and found no association.[86](#opo12675-bib-0086){ref-type="ref"}

Vitamin D can be produced in the dermis upon sunlight exposure or obtained through diet. There has been only one longitudinal population study regarding the role of vitamin D in AMD. This study found a decreased risk of developing nAMD when consuming a diet rich in vitamin D.[87](#opo12675-bib-0087){ref-type="ref"} However since the two most common dietary sources of vitamin D are milk and fish, it is possible that the association was more driven by the presence of omega‐3 fatty acids in the fish, rather than vitamin D.

### Carotenoids {#opo12675-sec-0064}

Carotenoids are organic pigments that are synthesised in plants and can be subdivided into carotenes and xanthophylls. Because humans are unable to synthesise carotenoids, they must be obtained through dietary consumption. The proposed protective mechanism of carotenoids for AMD is their ability to have an antioxidative effect through the absorptions of free electrons from ROS. Six carotenoids are commonly found in the human diet: α‐carotene, β‐carotene, β‐cryptoxanthin, lycopene, lutein and zeaxanthin.

α‐carotene and β‐carotene are both vitamin A precursors and have antioxidative properties. Both carotenes can be found in dark leafy vegetables such as spinach and kale, and yellow/orange vegetables such as carrots and bell peppers.

β‐carotene was added in the first supplement formula of the Age‐Related Eye Disease Study 1 (AREDS1) study (together with zinc, copper, vitamin C, and vitamin E) to investigate its properties to alter disease progression to central GA or neovascular AMD.[198](#opo12675-bib-0198){ref-type="ref"}

After five years follow‐up, 20% of patients with supplementation progressed to late stage AMD, while 28% of the patients with placebo progressed to late stage AMD. This risk reduction was only found in patients with at least intermediate stage AMD.

Other clinical trials with high‐dose β‐carotene supplementation reported an increased risk of lung cancer in smokers, which raised concerns regarding the prescription of the supplements according to the formula of the AREDS1 study in AMD patients, since a large proportion of the AMD population are smokers.[199](#opo12675-bib-0199){ref-type="ref"}, [200](#opo12675-bib-0200){ref-type="ref"} Therefore, supplementation according to the formula of the AREDS1 study became only a recommendation in non‐smokers with intermediate stage AMD.

Longitudinal population studies reported conflicting results between dietary α‐carotene and β‐carotene levels and AMD onset and disease progression. Higher levels of α‐carotene and β‐carotene were associated with decreased risk of early and late AMD in some studies,[194](#opo12675-bib-0194){ref-type="ref"}, [201](#opo12675-bib-0201){ref-type="ref"}, [202](#opo12675-bib-0202){ref-type="ref"} but most studies did not find any association.[189](#opo12675-bib-0189){ref-type="ref"}, [192](#opo12675-bib-0192){ref-type="ref"}, [194](#opo12675-bib-0194){ref-type="ref"}, [195](#opo12675-bib-0195){ref-type="ref"} Two studies reported even an increased risk of developing late AMD in those consuming higher levels of dietary β‐carotene.[196](#opo12675-bib-0196){ref-type="ref"}, [203](#opo12675-bib-0203){ref-type="ref"} Thus, the protective effect of β‐carotene (and α‐carotene) levels in AMD progression is not conclusive.

β‐cryptoxanthin is also a vitamin A precursor, closely related to β‐carotene and commonly found in the rinds of oranges, but also inside papaya and apples. Only one longitudinal population study found a protective effect of adhering to a β‐cryptoxanthin diet for developing late AMD,[201](#opo12675-bib-0201){ref-type="ref"} while three other studies did not find any association.[192](#opo12675-bib-0192){ref-type="ref"}, [194](#opo12675-bib-0194){ref-type="ref"}, [195](#opo12675-bib-0195){ref-type="ref"}

Lycopene is a red carotenoid found in tomatoes and bell peppers and has an antioxidative effect but no vitamin A activity. While some case‐control studies show lycopene levels are lower in patients with AMD compared to controls,[183](#opo12675-bib-0183){ref-type="ref"} longitudinal studies have not yet confirmed the protective effect of both systemic or dietary lycopene intake for the development and progression of AMD.[192](#opo12675-bib-0192){ref-type="ref"}, [194](#opo12675-bib-0194){ref-type="ref"}, [195](#opo12675-bib-0195){ref-type="ref"}, [201](#opo12675-bib-0201){ref-type="ref"}

Lutein and zeaxanthin are two carotenoids that are found in the macular pigment located in the ganglion cells, cone axons and Müller cells of the macula. Both carotenoids have antioxidative properties and a protective effect by absorbing hazardous blue and ultraviolet light before it can reach the photoreceptors.[204](#opo12675-bib-0204){ref-type="ref"} Foods rich in lutein and zeaxanthin are mainly dark‐leafy vegetables (spinach, kale) and yellow/orange vegetables (carrots, bell peppers).

The main aim of the AREDS2 study was to improve the supplement formula of the AREDS1 study by exploring the additional effect of lutein, zeaxanthin, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) to the formula, and to evaluate the effect of eliminating β‐carotene and lowering zinc doses.[205](#opo12675-bib-0205){ref-type="ref"}, [206](#opo12675-bib-0206){ref-type="ref"}

There was no difference in progression to late AMD in patients who used the AREDS supplements with lutein and zeaxanthin, compared with patients who only used the AREDS supplements. A subgroup analysis, however, did reveal a significant reduction in progression to late stage AMD in patients using the AREDS supplements with lutein and zeaxanthin and no β‐carotene, compared with patients using the AREDS supplements with β‐carotene (HR 0.82).[205](#opo12675-bib-0205){ref-type="ref"}

Several studies have shown a link between supplementation of lutein and zeaxanthin and higher systemic levels.[207](#opo12675-bib-0207){ref-type="ref"}, [208](#opo12675-bib-0208){ref-type="ref"} However, inconsistent findings have been reported on the relation between the systemic lutein and zeaxanthin concentrations and the macular pigment optical density (MPOD), which is a measurement of the amount of local macular pigment.[207](#opo12675-bib-0207){ref-type="ref"}, [208](#opo12675-bib-0208){ref-type="ref"}, [209](#opo12675-bib-0209){ref-type="ref"}

Longitudinal population studies are also not conclusive whether dietary lutein and zeaxanthin levels decrease disease progression. Half of these studies confirmed the protective effect of consuming higher dietary levels of lutein and zeaxanthin for the incidence of early AMD and progression to late AMD.[40](#opo12675-bib-0040){ref-type="ref"}, [196](#opo12675-bib-0196){ref-type="ref"}, [201](#opo12675-bib-0201){ref-type="ref"}, [202](#opo12675-bib-0202){ref-type="ref"} Others found no association for either lutein or zeaxanthin,[109](#opo12675-bib-0109){ref-type="ref"}, [190](#opo12675-bib-0190){ref-type="ref"}, [192](#opo12675-bib-0192){ref-type="ref"}, [194](#opo12675-bib-0194){ref-type="ref"}, [195](#opo12675-bib-0195){ref-type="ref"} and one study even reported an opposite effect.[210](#opo12675-bib-0210){ref-type="ref"} These conflicting results may partly be caused by the complex bioavailability of lutein and zeaxanthin caused by underlying pharmacogenomics, which makes the effect of lutein and zeaxanthin on disease progression more complex. Further prospective studies are needed to investigate whether the measurement of systemic lutein and zeaxanthin levels is useful to predict disease progression.

### Zinc {#opo12675-sec-0065}

Zinc is an essential trace element and plays a key role in many cellular processes such as DNA synthesis, RNA transcription, cell division, and prevention of cell apoptosis. In addition, zinc is essential for the development and maintenance of the immune system, including complement activation.[211](#opo12675-bib-0211){ref-type="ref"} In cells, the correct amount of zinc is regulated tightly by zinc transporters and storage proteins such as metallothioneins (MTs), which have antioxidative properties. There is evidence that due to ageing and oxidative stress the amount of MTs in the macula, and especially in the fovea, declines which triggers the release of zinc from MTs into the extracellular space where drusen formation occurs.[212](#opo12675-bib-0212){ref-type="ref"} Intracellular zinc depletion may also impair cellular metal homeostasis, induce apoptosis of RPE and retinal cells, and enhance oxidative stress and cell damage, causing the development of AMD.[213](#opo12675-bib-0213){ref-type="ref"} It is thought that zinc supplementation might trigger re‐uptake of zinc into the RPE‐choroid complex and increase the synthesis of MT, which helps to maintain retinal functions.[212](#opo12675-bib-0212){ref-type="ref"}

The AREDS1 trial showed that patients using zinc supplements (80 mg zinc oxide) have a lower progression rate to late AMD after six years when compared to controls (HR 0.71).[198](#opo12675-bib-0198){ref-type="ref"} In the AREDS2 trial, both the original zinc doses (80 mg) and lower‐dose zinc (25 mg) were associated with the same progression rate to late stage AMD, which suggested that lower‐dose zinc can also be used to alter disease progression.[206](#opo12675-bib-0206){ref-type="ref"}

Many longitudinal population studies show a protective effect of high dietary zinc intake for early and late AMD.[192](#opo12675-bib-0192){ref-type="ref"}, [194](#opo12675-bib-0194){ref-type="ref"}, [196](#opo12675-bib-0196){ref-type="ref"}, [202](#opo12675-bib-0202){ref-type="ref"} Interestingly, in an additional interaction analysis of the AREDS trial, the effectiveness of zinc appeared to differ by genotype.[171](#opo12675-bib-0171){ref-type="ref"} Currently, there are no studies on systemic zinc levels to predict disease progression. This is partly because systemic zinc levels in serum and plasma do not reflect zinc concentrations in cells, but also because systemic levels are influenced by many factors including age, sex and especially fasting.[214](#opo12675-bib-0214){ref-type="ref"}

Immune factors {#opo12675-sec-0066}
--------------

### Complement pathway {#opo12675-sec-0067}

The complement system is a key component of innate immunity. It protects the host from invading microorganisms (e.g. bacteria, viruses, and fungi) by providing inflammatory signals and eliminating pathogens and infected cells, but it also contributes to the homeostasis of the host by the clearance of apoptotic cells and cellular debris.[215](#opo12675-bib-0215){ref-type="ref"} Activation of the complement system can be initiated through three pathways: the classical pathway, alternative pathway, and the lectin pathway. In the eye, there is especially a continuous low‐grade activation of the alternative pathway.[216](#opo12675-bib-0216){ref-type="ref"} Via this pathway, complement activity is initiated by conversion of complement component 3, which leads to a cascade of conversions of inactive proteins to their active forms. Subsequently, convertases (C3‐ and C5‐ convertase) and anaphylatoxins are produced, which can initiate a feedback loop resulting in an exponential increase of activated complement components. Finally, the alternative pathway cascade results in the formation of the membrane attack complex, which causes cell lysis. To avoid tissue damage, complement activation is closely regulated by several complement inhibitory proteins, such as complement factor I (CFI) and complement factor H (CFH).[217](#opo12675-bib-0217){ref-type="ref"}

As mentioned in the section on complement genes, AMD is associated with many variants in genes encoding components and regulators of the complement system. Although the complement system acts locally in AMD, its components can also be measured systemically. Many case‐control studies have found differences in expression levels of systemic complement regulators and components between AMD patients and controls.[183](#opo12675-bib-0183){ref-type="ref"} However, it is not clear if systemic activation levels influence and/or reflect local complement activation in AMD. Currently, there are no prospective data on complement activation levels to predict disease progression, but, some studies have studied other systemic immune factors with disease progression (Table [S5](#opo12675-sup-0001){ref-type="supplementary-material"}).

### Cytokines {#opo12675-sec-0068}

Cytokines are a broad category of small proteins that are important in cell signalling and can be subdivided into interleukins, tumor necrosis factor, chemokines, and interferons. There are currently only a few studies that have investigated the predictive value of systemic interleukin and tumor necrosis factor levels for disease progression in AMD, possibly because previous case‐control studies did not find differences in systemic chemokine and interferon levels between AMD patients and controls.[183](#opo12675-bib-0183){ref-type="ref"}

Interleukins are a group of cytokines that are expressed by leukocytes and influence the function of the immune system. Interleukin 6 (IL‐6) is a cytokine produced by macrophages and T‐cells. Three prospective studies reported that systemic IL‐6 levels are positively correlated with the development of early AMD,[218](#opo12675-bib-0218){ref-type="ref"} progression to late AMD,[219](#opo12675-bib-0219){ref-type="ref"} and faster GA growth.[220](#opo12675-bib-0220){ref-type="ref"} Other interleukins, including IL‐1 β, IL‐8, and IL‐10, have also been studied in AMD, though to a lesser extent, and no relation has been found between these other interleukins and disease progression in AMD.[220](#opo12675-bib-0220){ref-type="ref"}

Tumor necrosis factor--α (TNF‐α) is a cytokine involved in cell activation, differentiation, and apoptosis and its receptor, TNF‐αR2, is expressed on the choroidal vascular cells, RPE, and on Müller cells in the retina. One longitudinal population study found a positive relation between TNF‐αR2 levels and early AMD development.[218](#opo12675-bib-0218){ref-type="ref"} However, other studies found no association with the development of late AMD or GA growth.[219](#opo12675-bib-0219){ref-type="ref"}, [220](#opo12675-bib-0220){ref-type="ref"}

### C‐reactive protein {#opo12675-sec-0069}

C‐reactive protein (CRP) is a protein of hepatic origin that increases following IL‐6 secretion. CRP activates the complement system through promoting phagocytosis by macrophages. Evidence of studies using CRP values to predict disease progression in AMD are inconclusive. Five prospective studies found no relation between systemic CRP levels and AMD progression.[88](#opo12675-bib-0088){ref-type="ref"}, [93](#opo12675-bib-0093){ref-type="ref"}, [94](#opo12675-bib-0094){ref-type="ref"}, [219](#opo12675-bib-0219){ref-type="ref"}, [220](#opo12675-bib-0220){ref-type="ref"} There is one study which used a more precise measurement of CRP (high‐sensitivity CRP \[hsCRP\]) and found a positive relationship with the development of early AMD.[218](#opo12675-bib-0218){ref-type="ref"}

### Intercellular‐ and Vascular Cell Adhesion Molecule 1 {#opo12675-sec-0070}

Intercellular adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM) regulate inflammation by attracting white blood cells and controlling their migration into the blood vessel wall. Complement‐mediated activation of choroidal endothelial secretion of ICAM and VCAM has been hypothesised to play a role in the pathogenesis of AMD. Two longitudinal population studies showed no association between systemic ICAM levels and disease progression to early AMD and late AMD.[218](#opo12675-bib-0218){ref-type="ref"}, [219](#opo12675-bib-0219){ref-type="ref"} However, one of these studies did find a positive relation between systemic VCAM levels and the development of early AMD.[218](#opo12675-bib-0218){ref-type="ref"}

### White blood cell count {#opo12675-sec-0071}

As discussed in the section on complement genes**,** genetic variants in complement genes are related to AMD, thus the immune system is linked to the pathogenesis of AMD. The increase of several immune components also causes cellular proliferation of immune cells increasing the white blood cell (WBC) count. A relatively large number of studies have investigated the WBC count and the progression of AMD but did not detect any association.[2](#opo12675-bib-0002){ref-type="ref"}, [40](#opo12675-bib-0040){ref-type="ref"}, [88](#opo12675-bib-0088){ref-type="ref"}, [218](#opo12675-bib-0218){ref-type="ref"} Nevertheless, WBCs may still be considered a potential risk factor for AMD progression since it is conceivable that it is not the total number of cells that change, but rather the ratio between different cell types.[183](#opo12675-bib-0183){ref-type="ref"}

Lipid factors {#opo12675-sec-0072}
-------------

Both case‐control studies and prospective studies show associations between several lipid factors and AMD.[183](#opo12675-bib-0183){ref-type="ref"} Table [S6](#opo12675-sup-0001){ref-type="supplementary-material"} shows an overview of different kinds of systemic lipid factors and their association with the development of early and late AMD, as identified in prospective cohort studies. Of note, most prospective studies investigating fatty acids have estimated the systemic levels based on food frequency questionnaires and only a minority of the studies have measured systemic blood levels.[127](#opo12675-bib-0127){ref-type="ref"}, [221](#opo12675-bib-0221){ref-type="ref"}, [222](#opo12675-bib-0222){ref-type="ref"}, [223](#opo12675-bib-0223){ref-type="ref"}, [224](#opo12675-bib-0224){ref-type="ref"}

### Lipids {#opo12675-sec-0073}

Cholesterol is an organic molecule biosynthesised by cells or ingested with the diet, and is an essential structural component of cell membranes, involved in several cell signalling processes, and a precursor for the biosynthesis of steroid hormones, bile acid, and vitamin D. The vast majority of studies did not find any relationship between systemic cholesterol levels and progression to early AMD, GA or nAMD.[40](#opo12675-bib-0040){ref-type="ref"}, [88](#opo12675-bib-0088){ref-type="ref"}, [93](#opo12675-bib-0093){ref-type="ref"}, [94](#opo12675-bib-0094){ref-type="ref"}, [108](#opo12675-bib-0108){ref-type="ref"}, [114](#opo12675-bib-0114){ref-type="ref"}, [115](#opo12675-bib-0115){ref-type="ref"}, [116](#opo12675-bib-0116){ref-type="ref"}, [146](#opo12675-bib-0146){ref-type="ref"}, [179](#opo12675-bib-0179){ref-type="ref"}, [225](#opo12675-bib-0225){ref-type="ref"} Only two studies found an association between serum cholesterol en the development of late stage AMD.[2](#opo12675-bib-0002){ref-type="ref"}, [111](#opo12675-bib-0111){ref-type="ref"} One of these studies reported that serum cholesterol levels have a protective effect on the development of nAMD (per 10 mg dL^−1^ cholesterol, OR 0.94), while they are a risk factor for the development of GA (per 10 mg dL^−1^ cholesterol, OR 1.08) over five years follow‐up.[2](#opo12675-bib-0002){ref-type="ref"}

Triglycerides are molecules consisting of glycerol bound to three fatty acids of variable length. Triglycerides are the main constituents of body fat and are also present in the blood to enable the transference of adipose fat and blood glucose. Most studies do not find a relation between systemic triglyceride levels and disease progression in AMD.[40](#opo12675-bib-0040){ref-type="ref"}, [93](#opo12675-bib-0093){ref-type="ref"}, [108](#opo12675-bib-0108){ref-type="ref"}, [111](#opo12675-bib-0111){ref-type="ref"}, [115](#opo12675-bib-0115){ref-type="ref"}, [146](#opo12675-bib-0146){ref-type="ref"} There is one prospective study that found a decreased risk of developing any AMD after 18 years follow‐up in patients having higher baseline systemic triglyceride levels.[88](#opo12675-bib-0088){ref-type="ref"}

### Lipoproteins {#opo12675-sec-0074}

Lipoproteins are biochemical proteins whose primary purpose is to transport hydrophobic lipids, such as cholesterol and triglycerides, through the circulation. Lipoproteins can be classified into five different lipoproteins, as based on their density and size: chylomicrons; very‐low‐density lipoprotein (VLDL); intermediate‐density lipoprotein (IDL); low‐density lipoprotein (LDL); and high‐density lipoprotein (HDL). Both LDL and HDL transport cholesterol between the liver and periphery and have been extensively studied for their association with the development of AMD and disease progression.

LDL‐cholesterol (LDL‐C) is the main carrier of cholesterol in the circulation. Five large longitudinal population studies have investigated the association between systemic LDL‐C levels and disease progression in AMD over different lengths of follow‐up ranging from two to 18 years. Nonetheless, none of these studies found an association with the development of early and late AMD.[88](#opo12675-bib-0088){ref-type="ref"}, [93](#opo12675-bib-0093){ref-type="ref"}, [108](#opo12675-bib-0108){ref-type="ref"}, [115](#opo12675-bib-0115){ref-type="ref"}, [146](#opo12675-bib-0146){ref-type="ref"}

Longitudinal population studies evaluating systemic HDL‐C levels in AMD show mixed results. The majority of the studies report that patients with increased levels of HDL‐C have an increased risk of developing early and late AMD,[93](#opo12675-bib-0093){ref-type="ref"}, [94](#opo12675-bib-0094){ref-type="ref"}, [108](#opo12675-bib-0108){ref-type="ref"}, [116](#opo12675-bib-0116){ref-type="ref"}, [146](#opo12675-bib-0146){ref-type="ref"}, [179](#opo12675-bib-0179){ref-type="ref"}, [225](#opo12675-bib-0225){ref-type="ref"} the minority of the studies show no relation,[2](#opo12675-bib-0002){ref-type="ref"}, [21](#opo12675-bib-0021){ref-type="ref"}, [88](#opo12675-bib-0088){ref-type="ref"}, [111](#opo12675-bib-0111){ref-type="ref"} and one prospective study reported an opposite effect.[115](#opo12675-bib-0115){ref-type="ref"} Some studies suggest that the changes in HDL composition and functionality might be more important for the development of AMD, rather than the total systemic circulation levels itself.[178](#opo12675-bib-0178){ref-type="ref"} Furthermore, there is growing evidence that HDL is directly involved in complement regulation and is able to transport specific complement components and regulators such as C3, CFB, C5 and C2.[178](#opo12675-bib-0178){ref-type="ref"}

### Apolipoproteins {#opo12675-sec-0075}

Apolipoproteins (apo) are structural proteins that bind triglycerides and cholesterol to form lipoproteins. During the development of AMD, it has been suggested that RPE cells secret Apo into the Bruch's membrane, forming a lipid barrier that retards the transportation of oxygen, nutrition, and waste products, which stimulates drusen formation. There are two longitudinal studies investigating systemic apolipoproteins and the progression of AMD.[111](#opo12675-bib-0111){ref-type="ref"}, [219](#opo12675-bib-0219){ref-type="ref"} Only one of these studies found that systemic ApoA1 levels, the major structural protein component of HDL, are associated with an increased risk of developing late AMD, while systemic ApoB levels, the primary apolipoproteins of the other four lipoproteins, are associated with a decreased risk for developing early AMD over 14 years follow‐up.[111](#opo12675-bib-0111){ref-type="ref"}

### Fatty acids {#opo12675-sec-0076}

Fatty acids consist of a carboxyl group with a hydrocarbon chain, which is either saturated or unsaturated. Fatty acids have different functions, including storage as triglycerides to be used as an energy substrate, the formation of cholesterol esters, and usage as structural components for cell membranes. Fatty acids are characterised by their number of carbon and double bonds. Saturated fatty acids (SFAs) have no double bond, monounsaturated fatty acids (MUFAs) have one double bond, and polyunsaturated fatty acids (PUFAs) have two or more double bonds. The latter can be subdivided into omega‐3 fatty acids and omega‐6 fatty acids, depending on the location of the first double bond. Studies suggest that metabolites derived from omega‐3, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are anti‐inflammatory and antiangiogenic, whereas those derived from omega‐6 are pro‐inflammatory and pro‐angiogenic.

All longitudinal population studies which investigated dietary intake of SFAs, including palmitic acid and stearic acids, found no relation with the development of early AMD or progression to late stage AMD.[89](#opo12675-bib-0089){ref-type="ref"}, [123](#opo12675-bib-0123){ref-type="ref"}, [124](#opo12675-bib-0124){ref-type="ref"}, [125](#opo12675-bib-0125){ref-type="ref"}, [126](#opo12675-bib-0126){ref-type="ref"}, [210](#opo12675-bib-0210){ref-type="ref"}, [226](#opo12675-bib-0226){ref-type="ref"}, [227](#opo12675-bib-0227){ref-type="ref"}

There are currently no longitudinal prospective studies that investigated systemic plasma or serum SFA levels with AMD progression.

Dietary intake of MUFAs, including oleic acids (OAs) and palmitoleic acids (PAs), have been extensively investigated for the development and progression of AMD. However, none of the longitudinal population studies found an association of dietary MUFA levels with the development of early AMD or progression to late stage AMD,[89](#opo12675-bib-0089){ref-type="ref"}, [123](#opo12675-bib-0123){ref-type="ref"}, [124](#opo12675-bib-0124){ref-type="ref"}, [125](#opo12675-bib-0125){ref-type="ref"}, [126](#opo12675-bib-0126){ref-type="ref"}, [210](#opo12675-bib-0210){ref-type="ref"}, [226](#opo12675-bib-0226){ref-type="ref"}, [227](#opo12675-bib-0227){ref-type="ref"} and there are currently no prospective studies that have evaluated plasma or serum MUFA levels on AMD progression.

Several dietary omega‐3 fatty acid levels have been investigated in AMD, including a‐linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Omega‐3 fatty acids are in high quantities found in fatty fish, which is a diet component that has been confirmed to reduce the risk of AMD development in multiple studies (see section Diet).

Whether increased dietary intake or higher systemic levels of ALA are associated AMD progression is not clear. Three longitudinal population studies showed no association between a higher dietary intake of ALA and AMD progression,[124](#opo12675-bib-0124){ref-type="ref"}, [126](#opo12675-bib-0126){ref-type="ref"}, [226](#opo12675-bib-0226){ref-type="ref"} and three prospective studies on systemic ALA levels reported conflicting results: one study showed that higher plasma ALA levels were associated with a decreased risk of developing GA and nAMD,[221](#opo12675-bib-0221){ref-type="ref"} while two other studies showed an increased risk of developing early and late AMD.[123](#opo12675-bib-0123){ref-type="ref"}, [224](#opo12675-bib-0224){ref-type="ref"}

Several longitudinal studies have investigated dietary intake and systemic levels of EPA and DHA in AMD. Half of these studies found a decreased risk of developing early or late AMD in patients consuming higher amounts of EPA,[202](#opo12675-bib-0202){ref-type="ref"}, [203](#opo12675-bib-0203){ref-type="ref"}, [228](#opo12675-bib-0228){ref-type="ref"} and the majority of longitudinal studies reported a decreased risk of developing early or late AMD when consuming higher amounts of DHA. [89](#opo12675-bib-0089){ref-type="ref"}, [123](#opo12675-bib-0123){ref-type="ref"}, [202](#opo12675-bib-0202){ref-type="ref"}, [203](#opo12675-bib-0203){ref-type="ref"}, [228](#opo12675-bib-0228){ref-type="ref"} Only a few prospective studies reported no relation between dietary intake of EPA[89](#opo12675-bib-0089){ref-type="ref"}, [123](#opo12675-bib-0123){ref-type="ref"}, [226](#opo12675-bib-0226){ref-type="ref"} or DHA[226](#opo12675-bib-0226){ref-type="ref"} and AMD. Based on the results of these epidemiological studies, two clinical trials have been conducted to investigate the value of omega‐3 supplementation to delay disease progression.

The Age‐Related Eye Disease Study 2 (AREDS2), a double‐blind trial in AMD patients, found no decreased risk of AMD progression after five years follow‐up in patients using EPA and DHA supplementation in addition to the original supplement formulation of the AREDS1 study (zinc, copper, vitamin C, vitamin E, and β‐carotene) when compared to patients using the original supplement formulation of the AREDS1 study only.[205](#opo12675-bib-0205){ref-type="ref"} However, some investigators suggested that the design of the AREDS2 trial might not have permitted the prophylactic potential of omega‐3 to be demonstrated.[178](#opo12675-bib-0178){ref-type="ref"}

Furthermore, the nutritional AMD Treatment 2 (NAT‐2) study, a double‐blind trial which investigated the effect of EPA and DHA supplementation in patients with early AMD in the study eye and neovascular AMD in the fellow eye, did also not find a decreased risk of nAMD development in the fellow‐eye after three years follow‐up.[223](#opo12675-bib-0223){ref-type="ref"} However, the investigators observed poor treatment compliance in the treatment group, demonstrated by a high variance in the systemic EPA/DHA levels in the red blood cell membrane. Interestingly, patients who maintained a consistently high EPA/DHA levels in the RBCM, and thus therapy compliance, had a reduced risk of developing late AMD in the fellow‐eye (HR 0.32). This finding is somewhat analogous to that observed in the majority of longitudinal population studies, which showed a reduced risk of AMD progression in patients with higher plasma or serum EPA and DHA levels.[127](#opo12675-bib-0127){ref-type="ref"}, [221](#opo12675-bib-0221){ref-type="ref"}, [222](#opo12675-bib-0222){ref-type="ref"} Therefore, systemic omega‐3 fatty acids levels, especially EPA and DHA measured in red blood cell membranes, seem to be a good indicator of dietary compliance and a systemic predictor of AMD progression.

Two kinds of omega‐6 fatty acids have been studied for disease progression in AMD: linoleic acid (LA) and arachidonic acid (AA). The majority of longitudinal studies found no association between dietary intake or systemic levels of LA or AA and AMD development.[89](#opo12675-bib-0089){ref-type="ref"}, [124](#opo12675-bib-0124){ref-type="ref"}, [126](#opo12675-bib-0126){ref-type="ref"}, [226](#opo12675-bib-0226){ref-type="ref"} Only one longitudinal population study reported an increased risk of developing AMD over 12 year follow‐up in patients with a high dietary intake of LA.[123](#opo12675-bib-0123){ref-type="ref"}

Personalised prediction of disease progression {#opo12675-sec-0077}
==============================================

Current prediction models {#opo12675-sec-0078}
-------------------------

For the development of personalised prediction models, accurate and easy quantification of risk factors is important. As discussed in the previous sections, numerous phenotypic, demographic, environmental, genetic and molecular risk factors have been described to be associated with disease progression in AMD. These risk factors can be combined in prediction models to predict disease progression, but the selection of the proper risk factors for personalised risk prediction will differ among individuals and may be dependent on their current disease stage. While phenotypic risk factors are more important to predict disease progression during the course of the disease, demographic, environmental, genetic and molecular risk factors may be more valuable at earlier disease stages. The prediction models developed to date include similar risk factors: phenotypic disease classification based on drusen and pigment abnormalities identified on CFP; demographic factors such as age and sex; environmental risk factors such as smoking and BMI; and a subset of AMD variants, including rs570618 in *CFH* and rs860846 in *ARMS2/HTRA1*.

*Table* [2](#opo12675-tbl-0002){ref-type="table"} provides an overview of 25 developed prediction models to predict late stage AMD, as developed in eight different population studies with follow‐up data ranging between 3--12 years. All these population studies used CFPs for identifying phenotypical characteristics. When only demographic risk factors such as age and gender are included, the prediction of late stage AMD is poor (AUC 0.60--0.64). Adding environmental risk factors such as BMI and smoking results in a better predicting performance (AUC 0.62--0.67). Next, adding genetic information or phenotypic information further improves the predictive performance of the models (AUC 0.75--0.86 and AUC 0.89--0.90, respectively). Finally, when phenotypic, demographic, environmental and genetic risk factors are combined, prediction models reach the highest discriminative performances (AUC of 0.87--0.96).[91](#opo12675-bib-0091){ref-type="ref"}, [92](#opo12675-bib-0092){ref-type="ref"}, [229](#opo12675-bib-0229){ref-type="ref"}, [230](#opo12675-bib-0230){ref-type="ref"}, [231](#opo12675-bib-0231){ref-type="ref"}, [232](#opo12675-bib-0232){ref-type="ref"} Of note, the highest AUC was found in a prediction model that only considered central GA as late stage AMD, meaning that patients having non‐central GA at baseline were also included to predict central GA.[231](#opo12675-bib-0231){ref-type="ref"} This might explain the high discriminative performances of the models from this study compared to the prediction models from other studies, since patients with non‐central GA have a higher risk for progression to central GA compared to patients with intermediate stage AMD.

###### 

Overview of prediction models for late stage age‐related macular degeneration (AMD), using combinations of risk factor categories (phenotypic, demographic, environmental, genetic and molecular) as developed in prospective cohort studies

  References                                                    Follow‐up (years)   Imaging modality   Definition progression to GA   Definition progression to nAMD                                     Phenotypic (P)   Demographic (D)   Environmental (E)   Genetic (G)   Molecular (M)   AUC
  ------------------------------------------------------------- ------------------- ------------------ ------------------------------ ------------------------------------------------------------------ ---------------- ----------------- ------------------- ------------- --------------- ------
  Buitendijk (2013)[239](#opo12675-bib-0239){ref-type="ref"}    10                  CFP                Central GA, non‐central GA     Retinal PED, subretinal fibrous tissue, hemorrhage, CNV membrane   --               D                 --                  --            --              0.60
  Sardell (2016)[90](#opo12675-bib-0090){ref-type="ref"}        3                   CFP                Central GA, non‐central GA     Serous PED, subretinal fibrous tissue, hemorrhage, CNV membrane    --               D                 --                  --            --              0.64
  Ding (2017)[229](#opo12675-bib-0229){ref-type="ref"}          10                  CFP                Central GA, non‐central GA     Retinal PED, haemorrhage, subretinal fibrous tissue                --               D                 E                   --            --              0.62
  Perlee (2013)[231](#opo12675-bib-0231){ref-type="ref"}        12                  CFP                Central GA                     Retinal PED, haemorrhage, subretinal fibrous tissue                --               D                 E                   --            --              0.63
  Seddon (2015)[91](#opo12675-bib-0091){ref-type="ref"}         10                  CFP                Central GA, non‐central GA     Serous PED, subretinal fibrous tissue, hemorrhage, CNV membrane    --               D                 E                   --            --              0.67
  Sardell (2016)[90](#opo12675-bib-0090){ref-type="ref"}        3                   CFP                Central GA, non‐central GA     Serous PED, subretinal fibrous tissue, hemorrhage, CNV membrane    --               D                 --                  G             --              0.67
  Buitendijk (2013) [239](#opo12675-bib-0239){ref-type="ref"}   10                  CFP                Central GA, non‐central GA     Retinal PED, subretinal fibrous tissue, hemorrhage, CNV membrane   --               D                 --                  G             --              0.82
  Ding (2017)[229](#opo12675-bib-0229){ref-type="ref"}          10                  CFP                Central GA, non‐central GA     Retinal PED, haemorrhage, subretinal fibrous tissue                --               D                 E                   G             --              0.75
  Seddon (2015)[91](#opo12675-bib-0091){ref-type="ref"}         10                  CFP                Central GA, non‐central GA     Serous PED, subretinal fibrous tissue, hemorrhage, CNV membrane    --               D                 E                   G             --              0.80
  Perlee (2013)[231](#opo12675-bib-0231){ref-type="ref"}        12                  CFP                Central GA                     Retinal PED, haemorrhage, subretinal fibrous tissue                --               D                 E                   G             --              0.86
  Seddon (2015)[91](#opo12675-bib-0091){ref-type="ref"}         10                  CFP                Central GA, non‐central GA     Serous PED, subretinal fibrous tissue, hemorrhage, CNV membrane    --               --                --                  G             --              0.79
  Perlee (2013)[231](#opo12675-bib-0231){ref-type="ref"}        12                  CFP                Central GA                     Retinal PED, haemorrhage, subretinal fibrous tissue                --               --                --                  G             --              0.84
  Ding (2017)[229](#opo12675-bib-0229){ref-type="ref"}          10                  CFP                Central GA, non‐central GA     Retinal PED, haemorrhage, subretinal fibrous tissue                P                --                --                  --            --              0.88
  Perlee (2013)[231](#opo12675-bib-0231){ref-type="ref"}        12                  CFP                Central GA                     Retinal PED, haemorrhage, subretinal fibrous tissue                P                --                --                  --            --              0.89
  Ding (2017)[229](#opo12675-bib-0229){ref-type="ref"}          10                  CFP                Central GA, non‐central GA     Retinal PED, haemorrhage, subretinal fibrous tissue                P                D                 E                   --            --              0.89
  Seddon (2015)[91](#opo12675-bib-0091){ref-type="ref"}         10                  CFP                Central GA, non‐central GA     Serous PED, subretinal fibrous tissue, hemorrhage, CNV membrane    P                D                 E                   --            --              0.90
  Perlee (2013)[231](#opo12675-bib-0231){ref-type="ref"}        12                  CFP                Central GA                     Retinal PED, haemorrhage, subretinal fibrous tissue                P                D                 E                   --            --              0.90
  Seddon (2015)[91](#opo12675-bib-0091){ref-type="ref"}         10                  CFP                Central GA, non‐central GA     Serous PED, subretinal fibrous tissue, hemorrhage, CNV membrane    P                --                --                  G             --              0.91
  Perlee (2013)[231](#opo12675-bib-0231){ref-type="ref"}        12                  CFP                Central GA                     Retinal PED, haemorrhage, subretinal fibrous tissue                P                --                --                  G             --              0.96
  Klein (2011)[230](#opo12675-bib-0230){ref-type="ref"}         5                   CFP                Central GA, non‐central GA     Retinal PED, haemorrhage, subretinal fibrous tissue                P                D                 E                   G             --              0.87
  Buitendijk (2013)[232](#opo12675-bib-0232){ref-type="ref"}    10                  CFP                Central GA, non‐central GA     Retinal PED, subretinal fibrous tissue, hemorrhage, CNV membrane   P                D                 E                   G             --              0.88
  Ding (2017)[229](#opo12675-bib-0229){ref-type="ref"}          10                  CFP                Central GA, non‐central GA     Retinal PED, haemorrhage, subretinal fibrous tissue                P                D                 E                   G             --              0.89
  Yu (2012)[92](#opo12675-bib-0092){ref-type="ref"}             10                  CFP                Central GA, non‐central GA     Serous PED, subretinal fibrous tissue, hemorrhage, CNV membrane    P                D                 E                   G             --              0.90
  Seddon (2015)[91](#opo12675-bib-0091){ref-type="ref"}         10                  CFP                Central GA, non‐central GA     Serous PED, subretinal fibrous tissue, hemorrhage, CNV membrane    P                D                 E                   G             --              0.91
  Perlee (2013)[231](#opo12675-bib-0231){ref-type="ref"}        12                  CFP                Central GA                     Retinal PED, haemorrhage, subretinal fibrous tissue                P                D                 E                   G             --              0.96

Phenotypic: AMD classifications based on drusen and pigment abnormalities; Demographic: age and sex; Environmental: smoking, BMI and in some studies level of education; Genetic: rs570618 or rs1061170 in *CFH*, rs3750846 or rs10490924 in *ARMS2/HTRA1*, and in some studies additional AMD variants; Molecular: there are currently no prospective studies using molecular risk factors in their prediction models.

AMD, age‐related macular degeneration; AUC, area under curve; CFP, colour fundus photography; CNV, choroid neovascularisation; D, demographic predictors; E, environmental predictors; G, genetic predictors; GA, Geographic Atrophy; M, molecular predictors; nAMD, neovascular age‐related macular degeneration; P, phenotypic predictors; PED, pigment epithelium detachment.
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Future prediction models {#opo12675-sec-0079}
========================

Despite a relatively high discriminative performance of the current prediction models for late stage AMD, they could be further improved by including other promising risk factors. Phenotypic risk factors in the current prediction models are all identified on CFP, while it is recommended to use a multimodal imaging approach to identify phenotypic risk factors.[233](#opo12675-bib-0233){ref-type="ref"} Using both CFP and OCT, additional features could be identified that are highly correlated with disease progression such as drusen types, hyperreflective foci, and pigment epithelial detachment. Additionally, OCTA can detect quiescent CNV/subclinical CNV, which may have a prognostic value for predicting exudative nAMD.[234](#opo12675-bib-0234){ref-type="ref"} However, this is currently still under investigation.

Secondly, the current prediction models only use a restricted set of genetic variants. For future development of prediction models and personalised prediction, using a wider set of AMD‐associated variants as discovered in the most recent GWAS[166](#opo12675-bib-0166){ref-type="ref"} may provide a more accurate genetic risk of individuals, and genetic risk scores can be calculated to establish the combined effect of all AMD‐associated genetic variants.[235](#opo12675-bib-0235){ref-type="ref"} In addition, rare variants should especially be taken into account in families with several members affected with AMD.[236](#opo12675-bib-0236){ref-type="ref"}

Thirdly, current prediction models do not include molecular risk factors, while these factors can be measured quantitatively.[237](#opo12675-bib-0237){ref-type="ref"} Because some molecular risk factors are potentially modifiable, this could help to implement personalised preventive strategies for AMD. Promising systemic molecular factors that might be predictive for disease progression are HDL‐C, DHA, EPA, zeaxanthin, and lutein. However, current studies on these molecular factors show conflicting results, possibly because of a variable bioavailability of these factors caused by fluctuating systemic levels and underlying pharmacogenomics effects.[238](#opo12675-bib-0238){ref-type="ref"} Thus, before introducing these molecular factors into prediction models, more prospective research is needed to explore which factors influence the bioavailability of these molecular factors. When these molecular risk factors are confirmed in additional studies, including such molecular risk factors in addition to phenotypic, demographic, environmental and genetic risk factors may further improve the accuracy of prediction models, help to design preventive strategies based on modifiable risk factors, and provide personalised advice.
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